Medroxyprogesterone acetate explained

Verifiedfields:verified
Watchedfields:verified
Verifiedrevid:307255781
Width:250
Width2:235
Pronounce: [1]
Tradename:Depo-Provera, others
Pregnancy Au:D
Routes Of Administration:By mouth, sublingual, intramuscular injection, subcutaneous injection
Class:Progestogen
Progestin; Progestogen ester; Antigonadotropin; Steroidal antiandrogen
Atc Prefix:G03
Atc Suffix:AC06
Atc Supplemental:,
Legal Au:S4
Legal Ca:Rx-only
Legal Ca Comment:[2]
Legal Us:Rx-only
Legal Status:Rx-only
Bioavailability:By mouth: ~100%
Protein Bound:88% (to albumin)[3]
Metabolism:Liver (hydroxylation (CYP3A4), reduction, conjugation)
Elimination Half-Life:By mouth: 12–33 hours[4]
: ~50 days[5]
: ~40 days[6]
Excretion:Urine (as conjugates)
Cas Number:71-58-9
Pubchem:6279
Iuphar Ligand:2879
Drugbank:DB00603
Chemspiderid:6043
Chebi:6716
Unii:C2QI4IOI2G
Kegg:C08150
Chembl:717
Synonyms:MPA; DMPA; Methylhydroxyprogesterone acetate; Methylacetoxyprogesterone; MAP; Methypregnone; Metipregnone; 6α-Methyl-17α-hydroxyprogesterone acetate; 6α-Methyl-17α-acetoxyprogesterone; 6α-Methyl-17α-hydroxypregn-4-ene-3,20-dione acetate; NSC-26386
Iupac Name:[(6''S'',8''R'',9''S'',10''R'',13''S'',14''S'',17''R'')-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1''H''-cyclopenta[''a'']phenanthren-17-yl] acetate
C:24
H:34
O:4
Smiles:C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C
Stdinchi:InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
Stdinchikey:PSGAAPLEWMOORI-PEINSRQWSA-N
Melting Point:207
Melting High:209

Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type.[7] It is used as a method of birth control and as a part of menopausal hormone therapy. It is also used to treat endometriosis, abnormal uterine bleeding, paraphilia, and certain types of cancer. The medication is available both alone and in combination with an estrogen. It is taken by mouth, used under the tongue, or by injection into a muscle or fat.[8]

Common side effects include menstrual disturbances such as absence of periods, abdominal pain, and headaches.[8] More serious side effects include bone loss, blood clots, allergic reactions, and liver problems.[8] Use is not recommended during pregnancy as it may harm the baby.[8] MPA is an artificial progestogen, and as such activates the progesterone receptor, the biological target of progesterone. It also has androgenic activity and weak glucocorticoid activity. Due to its progestogenic activity, MPA decreases the body's release of gonadotropins and can suppress sex hormone levels. It works as a form of birth control by preventing ovulation.[8]

MPA was discovered in 1956 and was introduced for medical use in the United States in 1959.[9] [10] [8] It is on the World Health Organization's List of Essential Medicines.[11] MPA is the most widely used progestin in menopausal hormone therapy and in progestogen-only birth control.[12] [13] DMPA is approved for use as a form of long-acting birth control in more than 100 countries. In 2021, it was the 238th most commonly prescribed medication in the United States, with more than 1million prescriptions.[14] [15]

Medical uses

The most common use of MPA is in the form of DMPA as a long-acting progestogen-only injectable contraceptive to prevent pregnancy in women. It is an extremely effective contraceptive when used with relatively high doses to prevent ovulation. MPA is also used in combination with an estrogen in menopausal hormone therapy in postmenopausal women to treat and prevent menopausal symptoms such as hot flashes, vaginal atrophy, and osteoporosis. It is used in menopausal hormone therapy specifically to prevent endometrial hyperplasia and cancer that would otherwise be induced by prolonged unopposed estrogen therapy in women with intact uteruses.[16] In addition to contraception and menopausal hormone therapy, MPA is used in the treatment of gynecological and menstrual disorders such as dysmenorrhea, amenorrhea, and endometriosis.[17] Along with other progestins, MPA was developed to allow for oral progestogen therapy, as progesterone (the progestogen hormone made by the human body) could not be taken orally for many decades before the process of micronization was developed and became feasible in terms of pharmaceutical manufacturing.[18]

DMPA reduces sex drive in men and is used as a form of chemical castration to control inappropriate or unwanted sexual behavior in those with paraphilias or hypersexuality, including in convicted sex offenders.[19] [20] DMPA has also been used to treat benign prostatic hyperplasia, as a palliative appetite stimulant for cancer patients, and at high doses (800 mg per day) to treat certain hormone-dependent cancers including endometrial cancer, renal cancer, and breast cancer.[21] [22] [23] MPA has also been prescribed in feminizing hormone therapy for transgender women due to its progestogenic and functional antiandrogenic effects.[24] It has been used to delay puberty in children with precocious puberty but is not satisfactory for this purpose as it is not able to completely suppress puberty.[25] DMPA at high doses has been reported to be definitively effective in the treatment of hirsutism as well.[26]

Though not used as a treatment for epilepsy, MPA has been found to reduce the frequency of seizures and does not interact with antiepileptic medications. MPA does not interfere with blood clotting and appears to improve blood parameters for women with sickle cell anemia. Similarly, MPA does not appear to affect liver metabolism, and may improve primary biliary cirrhosis and chronic active hepatitis. Women taking MPA may experience spotting shortly after starting the medication but is not usually serious enough to require medical intervention. With longer use amenorrhea (absence of menstruation) can occur as can irregular menstruation which is a major source of dissatisfaction, though both can result in improvements with iron deficiency and risk of pelvic inflammatory disease and often do not result in discontinuation of the medication.

Birth control

Depot medroxyprogesterone acetate (DMPA)
Width:250px
Bc Type:Hormonal
Tradename:Depo-Provera, Depo-SubQ Provera 104, others
Date First Use:1969
Rate Type:Failure
Perfect Failure%:0.2
Perfect Failure Ref:[27]
Typical Failure%:6
Duration Effect:3 months
(12–14 weeks)
Reversibility:3–18 months
User Reminders:Maximum interval is just under 3 months
Clinic Interval:12 weeks
Std Protection Yesno:No
Periods Advantage:Usually no periods from 2nd injection
Benefits:Especially good if poor pill compliance.
Reduced endometrial cancer risk.
Periods Disadvantage:Especially in first injection may be frequent spotting
Risks:Reduced bone density, which may reverse after discontinuation
Medical Notes:For those intending to start family, suggest switch 6 months prior to alternative method (e.g. POP) allowing more reliable return fertility.

DMPA, under brand names such as Depo-Provera and Depo-SubQ Provera 104, is used in hormonal birth control as a long-lasting progestogen-only injectable contraceptive to prevent pregnancy in women. It is given by intramuscular or subcutaneous injection and forms a long-lasting depot, from which it is slowly released over a period of several months. It takes one week to take effect if given after the first five days of the period cycle, and is effective immediately if given during the first five days of the period cycle. Estimates of first-year failure rates are about 0.3%.[28]

Effectiveness

Trussell's estimated perfect use first-year failure rate for DMPA as the average of failure rates in seven clinical trials at 0.3%.[28] [29] It was considered perfect use because the clinical trials measured efficacy during actual use of DMPA defined as being no longer than 14 or 15 weeks after an injection (i.e., no more than 1 or 2 weeks late for a next injection).

Prior to 2004, Trussell's typical use failure rate for DMPA was the same as his perfect use failure rate: 0.3%.[30]

In 2004, using the 1995 NSFG failure rate, Trussell increased (by 10 times) his typical use failure rate for DMPA from 0.3% to 3%.[28] [29]

Trussell did not use 1995 NSFG failure rates as typical use failure rates for the other two then newly available long-acting contraceptives, the Norplant implant (2.3%) and the ParaGard copper T 380A IUD (3.7%), which were (as with DMPA) an order of magnitude higher than in clinical trials. Since Norplant and ParaGard allow no scope for user error, their much higher 1995 NSFG failure rates were attributed by Trussell to contraceptive overreporting at the time of a conception leading to a live birth.[28] [35] [29]

Advantages

DMPA has a number of advantages and benefits:[36] [37]

The United Kingdom Department of Health has actively promoted Long Acting Reversible Contraceptive use since 2008, particularly for young people;[45] following on from the October 2005 National Institute for Health and Clinical Excellence guidelines.[46] Giving advice on these methods of contraception has been included in the 2009 Quality and Outcomes Framework "good practice" for primary care.[47]

Comparison

Proponents of bioidentical hormone therapy believe that progesterone offers fewer side effects and improved quality of life compared to MPA.[48] The evidence for this view has been questioned; MPA is better absorbed when taken by mouth, with a much longer elimination half-life leading to more stable blood levels[49] though it may lead to greater breast tenderness and more sporadic vaginal bleeding.[48] The two compounds do not differentiate in their ability to suppress endometrial hyperplasia,[48] nor does either increase the risk of pulmonary embolism.[50] The two medications have not been adequately compared in direct tests to clear conclusions about safety and superiority.[18]

Available forms

See also: Conjugated estrogens/medroxyprogesterone acetate, Estradiol/medroxyprogesterone acetate and Estradiol cypionate/medroxyprogesterone acetate.

MPA is available alone in the form of 2.5, 5, and 10 mg oral tablets, as a 150 mg/mL (1 mL) or 400 mg/mL (2.5 mL) microcrystalline aqueous suspension for intramuscular injection, and as a 104 mg (0.65 mL of 160 mg/mL) microcrystalline aqueous suspension for subcutaneous injection.[51] It has also been marketed in the form of 100, 200, 250, 400, and 500 mg oral tablets; 500 and 1,000 mg oral suspensions; and as a 50 mg/mL microcrystalline aqueous suspension for intramuscular injection.[52] [53] A 100 mg/mL microcrystalline aqueous suspension for intramuscular injection was previously available as well. In addition to single-drug formulations, MPA is available in the form of oral tablets in combination with conjugated estrogens (CEEs), estradiol, and estradiol valerate for use in menopausal hormone therapy, and is available in combination with estradiol cypionate in a microcrystalline aqueous suspension as a combined injectable contraceptive.

Depo-Provera is the brand name for a 150 mg microcrystalline aqueous suspension of DMPA that is administered by intramuscular injection. The shot must be injected into thigh, buttock, or deltoid muscle four times a year (every 11 to 13 weeks), and provides pregnancy protection instantaneously after the first injection.[54] Depo-subQ Provera 104 is a variation of the original intramuscular DMPA that is instead a 104 mg microcrystalline dose in aqueous suspension administered by subcutaneous injection. It contains 69% of the MPA found in the original intramuscular DMPA formulation. It can be injected using a smaller injection needle inserting the medication just below the skin, instead of into the muscle, in either the abdomen or thigh. This subcutaneous injection claims to reduce the side effects of DMPA while still maintaining all the same benefits of the original intramuscular DMPA.

Contraindications

MPA is not usually recommended because of unacceptable health risk or because it is not indicated in the following cases:[55] [56]

Conditions where the theoretical or proven risks usually outweigh the advantages of using DMPA:

Conditions which represent an unacceptable health risk if DMPA is used:

Conditions where use is not indicated and should not be initiated:

MPA is not recommended for use prior to menarche or before or during recovery from surgery.[57]

Side effects

In women, the most common adverse effects of MPA are acne, changes in menstrual flow, drowsiness, and can cause birth defects if taken by pregnant women. Other common side effects include breast tenderness, increased facial hair, decreased scalp hair, difficulty falling or remaining asleep, stomach pain, and weight loss or gain.[17] Lowered libido has been reported as a side effect of MPA in women.[58] DMPA can affect menstrual bleeding. After a year of use, 55% of women experience amenorrhea (missed periods); after two years, the rate rises to 68%. In the first months of use "irregular or unpredictable bleeding or spotting, or, rarely, heavy or continuous bleeding" was reported.[59] MPA does not appear to be associated with vitamin B12 deficiency.[60] Data on weight gain with DMPA likewise are inconsistent.

At high doses for the treatment of breast cancer, MPA can cause weight gain and can worsen diabetes mellitus and edema (particularly of the face). Adverse effects peak at five weeks, and are reduced with lower doses. Less frequent effects may include thrombosis (though it is not clear if this is truly a risk, it cannot be ruled out), painful urination, headache, nausea, and vomiting. When used as a form of androgen deprivation therapy in men, more frequent complaints include reduced libido, impotence, reduced ejaculate volume, and within three days, chemical castration. At extremely high doses (used to treat cancer, not for contraception) MPA may cause adrenal suppression and may interfere with carbohydrate metabolism, but does not cause diabetes.[61]

When used as a form of injected birth control, there is a delayed return of fertility. The average return to fertility is 9 to 10 months after the last injection, taking longer for overweight or obese women. By 18 months after the last injection, fertility is the same as that in former users of other contraceptive methods. Fetuses exposed to progestogens have demonstrated higher rates of genital abnormalities, low birth weight, and increased ectopic pregnancy particularly when MPA is used as an injected form of long-term birth control. A study of accidental pregnancies among poor women in Thailand found that infants who had been exposed to DMPA during pregnancy had a higher risk of low birth weight and an 80% greater-than-usual chance of dying in the first year of life.[62]

Mood changes

There have been concerns about a possible risk of depression and mood changes with progestins like MPA, and this has led to reluctance of some clinicians and women to use them.[63] [64] However, contrary to widely-held beliefs, most research suggests that progestins do not cause adverse psychological effects such as depression or anxiety. A 2018 systematic review of the relationship between progestin-based contraception and depression included three large studies of DMPA and reported no association between DMPA and depression.[65] According to a 2003 review of DMPA, the majority of published clinical studies indicate that DMPA is not associated with depression, and the overall data support the notion that the medication does not significantly affect mood.[66]

In the largest study to have assessed the relationship between MPA and depression to date, in which over 3,900 women were treated with DMPA for up to 7 years, the incidence of depression was infrequent at 1.5% and the discontinuation rate due to depression was 0.5%.[67] [68] This study did not include baseline data on depression, and due to the incidence of depression in the study, the FDA required package labeling for DMPA stating that women with depression should be observed carefully and that DMPA should be discontinued if depression recurs. A subsequent study of 495 women treated with DMPA over the course of 1 year found that the mean depression score slightly decreased in the whole group of continuing users from 7.4 to 6.7 (by 9.5%) and decreased in the quintile of that group with the highest depression scores at baseline from 15.4 to 9.5 (by 38%). Based on the results of this study and others, a consensus began emerging that DMPA does not in fact increase the risk of depression nor worsen the severity of pre-existing depression.[69]

Similarly to the case of DMPA for hormonal contraception, the Heart and Estrogen/Progestin Replacement Study (HERS), a study of 2,763 postmenopausal women treated with 0.625 mg/day oral CEEs plus 2.5 mg/day oral MPA or placebo for 36 months as a method of menopausal hormone therapy, found no change in depressive symptoms.[70] [71] [72] However, some small studies have reported that progestins like MPA might counteract beneficial effects of estrogens against depression.[73]

Long-term effects

The Women's Health Initiative investigated the use of a combination of oral CEEs and MPA compared to placebo. The study was prematurely terminated when previously unexpected risks were discovered, specifically the finding that though the all-cause mortality was not affected by the hormone therapy, the benefits of menopausal hormone therapy (reduced risk of hip fracture, colorectal and endometrial cancer and all other causes of death) were offset by increased risk of coronary heart disease, breast cancer, strokes and pulmonary embolism.[74]

When combined with CEEs, MPA has been associated with an increased risk of breast cancer, dementia, and thrombus in the eye. In combination with estrogens in general, MPA may increase the risk of cardiovascular disease, with a stronger association when used by postmenopausal women also taking CEEs. It was because of these unexpected interactions that the Women's Health Initiative study was ended early due to the extra risks of menopausal hormone therapy,[75] resulting in a dramatic decrease in both new and renewal prescriptions for hormone therapy.[76]

Long-term studies of users of DMPA have found slight or no increased overall risk of breast cancer. However, the study population did show a slightly increased risk of breast cancer in recent users (DMPA use in the last four years) under age 35, similar to that seen with the use of combined oral contraceptive pills.[59]

Blood clots

DMPA has been associated in multiple studies with a higher risk of venous thromboembolism (VTE) when used as a form of progestogen-only birth control in premenopausal women.[77] [78] [79] [80] The increase in incidence of VTE ranges from 2.2-fold to 3.6-fold. Elevated risk of VTE with DMPA is unexpected, as DMPA has little or no effect on coagulation and fibrinolytic factors,[81] [82] and progestogens by themselves normally do not increase the risk of thrombosis. It has been argued that the higher incidence with DMPA has reflected preferential prescription of DMPA to women considered to be at an increased risk of VTE. Alternatively, it is possible that MPA may be an exception among progestins in terms of VTE risk.[83] [84] [85] A 2018 meta-analysis reported that MPA was associated with a 2.8-fold higher risk of VTE than other progestins. It is possible that the glucocorticoid activity of MPA may increase the risk of VTE.

Bone density

DMPA may cause reduced bone density in premenopausal women and in men when used without an estrogen, particularly at high doses, though this appears to be reversible to a normal level even after years of use.

On 17 November 2004, the United States Food and Drug Administration put a black box warning on the label, indicating that there were potential adverse effects of loss of bone mineral density.[86] [87] While it causes temporary bone loss, most women fully regain their bone density after discontinuing use.[88] The World Health Organization (WHO) recommends that the use not be restricted.[89] [90] The American College of Obstetricians and Gynecologists notes that the potential adverse effects on BMD be balanced against the known negative effects of unintended pregnancy using other birth control methods or no method, particularly among adolescents.

Three studies have suggested that bone loss is reversible after the discontinuation of DMPA.[91] [92] [93] Other studies have suggested that the effect of DMPA use on postmenopausal bone density is minimal,[94] perhaps because DMPA users experience less bone loss at menopause.[95] Use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density.[96]

The FDA recommends that DMPA not be used for longer than two years, unless there is no viable alternative method of contraception, due to concerns over bone loss.[87] However, a 2008 Committee Opinion from the American Congress of Obstetricians and Gynecologists (ACOG) advises healthcare providers that concerns about bone mineral density loss should neither prevent the prescription of or continuation of DMPA beyond two years of use.[97]

HIV risk

There is uncertainty regarding the risk of HIV acquisition among DMPA users; some observational studies suggest an increased risk of HIV acquisition among women using DMPA, while others do not.[98] The World Health Organization issued statements in February 2012 and July 2014 saying the data did not warrant changing their recommendation of no restriction – Medical Eligibility for Contraception (MEC) category 1 – on the use of DMPA in women at high risk for HIV.[99] [100] Two meta-analyses of observational studies in sub-Saharan Africa were published in January 2015.[101] They found a 1.4- to 1.5-fold increase risk of HIV acquisition for DMPA users relative to no hormonal contraceptive use.[102] [103] In January 2015, the Faculty of Sexual & Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists issued a statement reaffirming that there is no reason to advise against use of DMPA in the United Kingdom even for women at 'high risk' of HIV infection.[104] A systematic review and meta-analysis of risk of HIV infection in DMPA users published in fall of 2015 stated that "the epidemiological and biological evidence now make a compelling case that DMPA adds significantly to the risk of male-to-female HIV transmission."[105] In 2019, a randomized controlled trial found no significant association between DMPA use and HIV.[106]

Breastfeeding

MPA may be used by breastfeeding mothers. Heavy bleeding is possible if given in the immediate postpartum time and is best delayed until six weeks after birth. It may be used within five days if not breast feeding. While a study showed "no significant difference in birth weights or incidence of birth defects" and "no significant alternation of immunity to infectious disease caused by breast milk containing DMPA", a subgroup of babies whose mothers started DMPA at two days postpartum had a 75% higher incidence of doctor visits for infectious diseases during their first year of life.[107]

A larger study with longer follow-up concluded that "use of DMPA during pregnancy or breastfeeding does not adversely affect the long-term growth and development of children". This study also noted that "children with DMPA exposure during pregnancy and lactation had an increased risk of suboptimal growth in height," but that "after adjustment for socioeconomic factors by multiple logistic regression, there was no increased risk of impaired growth among the DMPA-exposed children." The study also noted that effects of DMPA exposure on puberty require further study, as so few children over the age of 10 were observed.[108]

Overdose

MPA has been studied at "massive" dosages of up to 5,000 mg per day orally and 2,000 mg per day via intramuscular injection, without major tolerability or safety issues described.[109] [110] Overdose is not described in the Food and Drug Administration (FDA) product labels for injected MPA (Depo-Provera or Depo-SubQ Provera 104). In the FDA product label for oral MPA (Provera), it is stated that overdose of an estrogen and progestin may cause nausea and vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding. According to the label, treatment of overdose should consist of discontinuation of MPA therapy and symptomatic care.

Interactions

MPA increases the risk of breast cancer, dementia, and thrombus when used in combination with CEEs to treat menopausal symptoms.[57] When used as a contraceptive, MPA does not generally interact with other medications. The combination of MPA with aminoglutethimide to treat metastases from breast cancer has been associated with an increase in depression.[61] St John's wort may decrease the effectiveness of MPA as a contraceptive due to acceleration of its metabolism.[57]

Pharmacology

Pharmacodynamics

MPA acts as an agonist of the progesterone, androgen, and glucocorticoid receptors (PR, AR, and GR, respectively), activating these receptors with EC50 values of approximately 0.01 nM, 1 nM, and 10 nM, respectively.[111] It has negligible affinity for the estrogen receptor. The medication has relatively high affinity for the mineralocorticoid receptor, but in spite of this, it has no mineralocorticoid or antimineralocorticoid activity. The intrinsic activities of MPA in activating the PR and the AR have been reported to be at least equivalent to those of progesterone and dihydrotestosterone (DHT), respectively, indicating that it is a full agonist of these receptors.[112] [113]

Relative affinities (%) of MPA and related steroids
50 0 0 10 100
67 5 0 8 0
90 6 0 6 8
Medroxyprogesterone acetate 115 5 0 29 160
65 5 0 30 0
Notes: Values are percentages (%). Reference ligands (100%) were promegestone for the, metribolone for the, estradiol for the, dexamethasone for the, and aldosterone for the . Sources:

Progestogenic activity

MPA is a potent agonist of the progesterone receptor with similar affinity and efficacy relative to progesterone.[114] While both MPA and its deacetylated analogue medroxyprogesterone bind to and agonize the PR, MPA has approximately 100-fold higher binding affinity and transactivation potency in comparison. As such, unlike MPA, medroxyprogesterone is not used clinically, though it has seen some use in veterinary medicine. The oral dosage of MPA required to inhibit ovulation (i.e., the effective contraceptive dosage) is 10 mg/day, whereas 5 mg/day was not sufficient to inhibit ovulation in all women.[115] In accordance, the dosage of MPA used in oral contraceptives in the past was 10 mg per tablet. For comparison to MPA, the dosage of progesterone required to inhibit ovulation is 300 mg/day, whereas that of the 19-nortestosterone derivatives norethisterone and norethisterone acetate is only 0.4 to 0.5 mg/day.[116]

The mechanism of action of progestogen-only contraceptives like DMPA depends on the progestogen activity and dose. High-dose progestogen-only contraceptives, such as DMPA, inhibit follicular development and prevent ovulation as their primary mechanism of action.[117] [118] The progestogen decreases the pulse frequency of gonadotropin-releasing hormone (GnRH) release by the hypothalamus, which decreases the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by the anterior pituitary. Decreased levels of FSH inhibit follicular development, preventing an increase in estradiol levels. Progestogen negative feedback and the lack of estrogen positive feedback on LH release prevent a LH surge. Inhibition of follicular development and the absence of a LH surge prevent ovulation.[119] [120] A secondary mechanism of action of all progestogen-containing contraceptives is inhibition of sperm penetration by changes in the cervical mucus.[121] Inhibition of ovarian function during DMPA use causes the endometrium to become thin and atrophic. These changes in the endometrium could, theoretically, prevent implantation. However, because DMPA is highly effective in inhibiting ovulation and sperm penetration, the possibility of fertilization is negligible. No available data support prevention of implantation as a mechanism of action of DMPA.[121]

MPA and related steroids at the progesterone receptor
Compound (nM) (nM)a (nM)b
4.3 0.9 25
241 47 32
Medroxyprogesterone acetate 1.2 0.6 0.15
Footnotes: a = Coactivator recruitment. b = Reporter cell line. Sources:
Oral potencies of MPA and related steroids
Progestogen
(mg/day)
(mg/cycle)
(mg/day)
(mg/day)
(mg/day)
300 4200 200–300 – 200
1.7 20–30 10 2.0 5–10
1.0 20 1.0 2.0 1.0
Medroxyprogesterone acetate 10 50 5–10 ? 5.0
? 50 ? ? 5.0
Abbreviations: OID = ovulation-inhibiting dosage (without additional estrogen). TFD = endometrial transformation dosage. ODP = oral dosage in commercial contraceptive preparations. ECD = estimated comparable dosage. Sources:[122] [123]

Antigonadotropic and anticorticotropic effects

MPA suppresses the hypothalamic–pituitary–adrenal (HPA) and hypothalamic–pituitary–gonadal (HPG) axes at sufficient dosages, resulting decreased levels of gonadotropins, androgens, estrogens, adrenocorticotropic hormone (ACTH), and cortisol, as well as levels of sex hormone-binding globulin (SHBG).[124] There is evidence that the suppressive effects of MPA on the HPG axis are mediated by activation of both the PR and the AR in the pituitary gland.[125] [126] Due to its effects on androgen levels, MPA can produce strong functional antiandrogenic effects, and is used in the treatment of androgen-dependent conditions such as precocious puberty in boys and hypersexuality in men.[127] In addition, since the medication suppresses estrogen levels as well, MPA can produce strong functional antiestrogenic effects similarly, and has been used to treat estrogen-dependent conditions such as precocious puberty in girls and endometriosis in women. Due to low estrogen levels, the use of MPA without an estrogen poses a risk of decreased bone mineral density and other symptoms of estrogen deficiency.[128]

Oral MPA has been found to suppress testosterone levels in men by about 30% (from 831 ng/dL to 585 ng/dL) at a dosage of 20 mg/day, by about 45–75% (average 60%; to 150–400 ng/dL) at a dosage of 60 mg/day,[129] [130] and by about 70–75% (from 832 to 862 ng/dL to 214 to 251 ng/dL) at a dosage of 100 mg/day.[131] [132] Dosages of oral MPA of 2.5 to 30 mg/day in combination with estrogens have been used to help suppress testosterone levels in transgender women.[133] [134] [135] [136] [137] [138] One study of injectable MPA in men with benign prostatic hyperplasia reported that a single 150 mg dose suppressed testosterone levels into the defined male castrate range (<58 ng/dL) within 7 days and that castration levels of testosterone were maintained for 3 months.[139] Very high doses of intramuscular MPA of 150 to 500 mg per week (but up to 900 mg per week) have similarly been reported to suppress testosterone levels to less than 100 ng/dL.[140] The typical initial dose of intramuscular MPA for testosterone suppression in men with paraphilias is 400 or 500 mg per week.

Androgenic activity

MPA is a potent full agonist of the AR. Its activation of the AR may play an important and major role in its antigonadotropic effects and in its beneficial effects against breast cancer.[141] [142] However, although MPA may produce androgenic side effects such as acne and hirsutism in some women,.[143] [144] In fact, likely due to its suppressive actions on androgen levels, it has been reported that MPA is generally highly effective in improving pre-existing symptoms of hirsutism in women with the condition.[145] [146] However, MPA has been seen to cause androgenic effects in children with precocious puberty.[147] The reason for the general lack of virilizing effects with MPA, despite it binding to and activating the AR with high affinity and this action potentially playing an important role in many of its physiological and therapeutic effects, is not entirely clear. However, MPA has been found to interact with the AR differently compared to other agonists of the receptor such as dihydrotestosterone (DHT).[112] The result of this difference appears to be that MPA binds to the AR with a similar affinity and intrinsic activity to that of DHT, but requires about 100-fold higher concentrations for a comparable induction of gene transcription, while at the same time not antagonizing the transcriptional activity of normal androgens like DHT at any concentration. Thus, this may explain the low propensity of MPA for producing androgenic side effects.

MPA shows weak androgenic effects on liver protein synthesis, similarly to other weakly androgenic progestins like megestrol acetate and 19-nortestosterone derivatives. While it does not antagonize estrogen-induced increases in levels of triglycerides and HDL cholesterol, DMPA every other week may decrease levels of HDL cholesterol. In addition, MPA has been found to suppress sex hormone-binding globulin (SHBG) production by the liver.[148] [149] At a dosage of 10 mg/day oral MPA, it has been found to decrease circulating SHBG levels by 14–18% in women taking 4 mg/day oral estradiol valerate. Conversely, in a study that combined 2.5 mg/day oral MPA with various oral estrogens, no influence of MPA on estrogen-induced increases in SHBG levels was discerned. In another, higher-dose study, SHBG levels were lower by 59% in a group of women treated with 50 mg/day oral MPA alone relative to an untreated control group of women. In massive-dose studies of oral or injectable MPA (e.g., 500–1,000 mg/day), the medication decreased SHBG levels by about 80%.[150] [151] [152]

Unlike the related steroids megestrol acetate and cyproterone acetate, MPA is not an antagonist of the AR and does not have direct antiandrogenic activity. As such, although MPA is sometimes described as an antiandrogen, it is not a "true" antiandrogen (i.e., AR antagonist).[153]

Glucocorticoid activity

As an agonist of the GR, MPA has glucocorticoid activity, and as a result can cause symptoms of Cushing's syndrome,[154] steroid diabetes, and adrenal insufficiency at sufficiently high doses. It has been suggested that the glucocorticoid activity of MPA may contribute to bone loss.[155] The glucocorticoid activity of MPA may also result in an upregulation of the thrombin receptor in blood vessel walls, which may contribute to procoagulant effects of MPA and risk of venous thromboembolism and atherosclerosis.[7] The relative glucocorticoid activity of MPA is among the highest of the clinically used progestins.

Steroidogenesis inhibition

See also: Steroidogenesis inhibitor and Neurosteroidogenesis inhibitor.

MPA has been found to act as a competitive inhibitor of rat 3α-hydroxysteroid dehydrogenase (3α-HSD).[156] [157] [158] [159] This enzyme is essential for the transformation of progesterone, deoxycorticosterone, and DHT into inhibitory neurosteroids such as allopregnanolone,, and 3α-androstanediol, respectively.[160] MPA has been described as very potent in its inhibition of rat 3α-HSD, with an IC50 of 0.2 μM and a Ki (in rat testicular homogenates) of 0.42 μM. However, inhibition of 3α-HSD by MPA does not appear to have been confirmed using human proteins yet, and the concentrations required with rat proteins are far above typical human therapeutic concentrations.

MPA has been identified as a competitive inhibitor of human 3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase II (3β-HSD II).[161] This enzyme is essential for the biosynthesis of sex steroids and corticosteroids. The Ki of MPA for inhibition of 3β-HSD II is 3.0 μM, and this concentration is reportedly near the circulating levels of the medication that are achieved by very high therapeutic dosages of MPA of 5 to 20 mg/kg/day (dosages of 300 to 1,200 mg/day for a 60 kg (132 lb) person). Aside from 3β-HSD II, other human steroidogenic enzymes, including cholesterol side-chain cleavage enzyme (P450scc/CYP11A1) and 17α-hydroxylase/17,20-lyase (CYP17A1), were not found to be inhibited by MPA. MPA has been found to be effective in the treatment of gonadotropin-independent precocious puberty and in breast cancer in postmenopausal women at high dosages, and inhibition of 3β-HSD II could be responsible for its effectiveness in these conditions.

GABAA receptor allosteric modulation

Progesterone, via transformation into neurosteroids such as 5α-dihydroprogesterone, 5β-dihydroprogesterone, allopregnanolone, and pregnanolone (catalyzed by the enzymes 5α- and 5β-reductase and 3α- and 3β-HSD), is a positive allosteric modulator of the GABAA receptor, and is associated with a variety of effects mediated by this property including dizziness, sedation, hypnotic states, mood changes, anxiolysis, and cognitive/memory impairment, as well as effectiveness as an anticonvulsant in the treatment of catamenial epilepsy.[162] It has also been found to produce anesthesia via this action in animals when administered at sufficiently high dosages. MPA was found to significantly reduce seizure incidence when added to existing anticonvulsant regimens in 11 of 14 women with uncontrolled epilepsy, and has also been reported to induce anesthesia in animals, raising the possibility that it might modulate the GABAA receptor similarly to progesterone.[163] [164]

MPA shares some of the same metabolic routes of progesterone and, analogously, can be transformed into metabolites such as 5α-dihydro-MPA (DHMPA) and 3α,5α-tetrahydro-MPA (THMPA). However, unlike the reduced metabolites of progesterone, DHMPA and THMPA have been found not to modulate the GABAA receptor. Conversely, unlike progesterone, MPA itself actually modulates the GABAA receptor, although notably not at the neurosteroid binding site. However, rather than act as a potentiator of the receptor, MPA appears to act as a negative allosteric modulator. Whereas the reduced metabolites of progesterone enhance binding of the benzodiazepine flunitrazepam to the GABAA receptor in vitro, MPA can partially inhibit the binding of flunitrazepam by up to 40% with half-maximal inhibition at 1 μM. However, the concentrations of MPA required for inhibition are high relative to therapeutic concentrations, and hence, this action is probably of little or no clinical relevance. The lack of potentiation of the GABAA receptor by MPA or its metabolites is surprising in consideration of the apparent anticonvulsant and anesthetic effects of MPA described above, and they remain unexplained.

Clinical studies using massive dosages of up to 5,000 mg/day oral MPA and 2,000 mg/day intramuscular MPA for 30 days in women with advanced breast cancer have reported "no relevant side effects", which suggests that MPA has no meaningful direct action on the GABAA receptor in humans even at extremely high dosages.[165]

Appetite stimulation

Although MPA and the closely related medication megestrol acetate are effective appetite stimulants at very high dosages,[166] the mechanism of action of their beneficial effects on appetite is not entirely clear. However, glucocorticoid, cytokine, and possibly anabolic-related mechanisms are all thought to possibly be involved, and a number of downstream changes have been implicated, including stimulation of the release of neuropeptide Y in the hypothalamus, modulation of calcium channels in the ventromedial hypothalamus, and inhibition of the secretion of proinflammatory cytokines including IL-1α, IL-1β, IL-6, and TNF-α, actions that have all been linked to an increase in appetite.[167]

Other activity

MPA weakly stimulates the proliferation of MCF-7 breast cancer cells in vitro, an action that is independent of the classical PRs and is instead mediated via the progesterone receptor membrane component-1 (PGRMC1).[168] Certain other progestins are also active in this assay, whereas progesterone acts neutrally. It is unclear if these findings may explain the different risks of breast cancer observed with progesterone, dydrogesterone, and other progestins such as medroxyprogesterone acetate and norethisterone in clinical studies.[169]

Pharmacokinetics

Absorption

Surprisingly few studies have been conducted on the pharmacokinetics of MPA at postmenopausal replacement dosages. The bioavailability of MPA with oral administration is approximately 100%. A single oral dose of 10 mg MPA has been found to result in peak MPA levels of 1.2 to 5.2 ng/mL within 2 hours of administration using radioimmunoassay.[170] [171] Following this, levels of MPA decreased to 0.09 to 0.35 ng/mL 12 hours post-administration. In another study, peak levels of MPA were 3.4 to 4.4 ng/mL within 1 to 4 hours of administration of 10 mg oral MPA using radioimmunoassay.[172] Subsequently, MPA levels fell to 0.3 to 0.6 ng/mL 24 hours after administration. In a third study, MPA levels were 4.2 to 4.4 ng/mL after an oral dose of 5 mg MPA and 6.0 ng/mL after an oral dose of 10 mg MPA, both using radioimmunoassay as well.[173]

Treatment of postmenopausal women with 2.5 or 5 mg/day MPA in combination with estradiol valerate for two weeks has been found to rapidly increase circulating MPA levels, with steady-state concentrations achieved after three days and peak concentrations occurring 1.5 to 2 hours after ingestion. With 2.5 mg/day MPA, levels of the medication were 0.3 ng/mL (0.8 nmol/L) in women under 60 years of age and 0.45 ng/mL (1.2 nmol/L) in women 65 years of age or over, and with 5 mg/day MPA, levels were 0.6 ng/mL (1.6 nmol/L) in women under 60 years of age and in women 65 years of age or over. Hence, area-under-curve levels of the medication were 1.6 to 1.8 times higher in those who were 65 years of age or older relative to those who were 60 years of age or younger. As such, levels of MPA have been found to vary with age, and MPA may have an increased risk of side effects in elderly postmenopausal women. This study assessed MPA levels using liquid-chromatography–tandem mass spectrometry (LC–MS/MS), a more accurate method of blood determinations.[174]

Oral MPA tablets can be administered sublingually instead of orally.[175] [176] [177] Rectal administration of MPA has also been studied.[178]

With intramuscular administration of 150 mg microcrystalline MPA in aqueous suspension, the medication is detectable in the circulation within 30 minutes, serum concentrations vary but generally plateau at 1.0 ng/mL (2.6 nmol/L) for 3 months.[179] Following this, there is a gradual decline in MPA levels, and the medication can be detected in the circulation for as long as 6 to 9 months post-injection. The particle size of MPA crystals significantly influences its rate of absorption into the body from the local tissue depot when used as a microcrystalline aqueous suspension via intramuscular injection.[180] [181] [182] Smaller crystals dissolve faster and are absorbed more rapidly, resulting in a shorter duration of action. Particle sizes can differ between different formulations of MPA, potentially influencing clinical efficacy and tolerability.[183]

Distribution

The plasma protein binding of MPA is 88%. It is weakly bound to albumin and is not bound to sex hormone-binding globulin or corticosteroid-binding globulin.

Metabolism

The elimination half-life of MPA via oral administration has been reported as both 11.6 to 16.6 hours and 33 hours, whereas the elimination half-lives with intramuscular and subcutaneous injection of microcrystalline MPA in aqueous suspension are 50 and 40 days, respectively. The metabolism of MPA is mainly via hydroxylation, including at positions C6β, C21, C2β, and C1β, mediated primarily via CYP3A4, but 3- and 5-dihydro and 3,5-tetrahydro metabolites of MPA are also formed. Deacetylation of MPA and its metabolites (into, e.g., medroxyprogesterone) has been observed to occur in non-human primate research to a substantial extent as well (30 to 70%).[184] MPA and/or its metabolites are also metabolized via conjugation. The C6α methyl and C17α acetoxy groups of MPA make it more resistant to metabolism and allow for greater bioavailability than oral progesterone.[185]

Elimination

MPA is eliminated 20 to 50% in urine and 5 to 10% in feces following intravenous administration.[186] Less than 3% of a dose is excreted in unconjugated form.

Level–effect relationships

With intramuscular administration, the high levels of MPA in the blood inhibit luteinizing hormone and ovulation for several months, with an accompanying decrease in serum progesterone to below 0.4 ng/mL. Ovulation resumes when once blood levels of MPA fall below 0.1 ng/mL. Serum estradiol remains at approximately 50 pg/mL for approximately four months post-injection (with a range of 10–92 pg/mL after several years of use), rising once MPA levels fall below 0.5 ng/mL.

Hot flashes are rare while MPA is found at significant blood levels in the body, and the vaginal lining remains moist and creased. The endometrium undergoes atrophy, with small, straight glands and a stroma that is decidualized. Cervical mucus remains viscous. Because of its steady blood levels over the long term and multiple effects that prevent fertilization, MPA is a very effective means of birth control.[179]

Time–concentration curves

Chemistry

See also: List of progestogens, Progestogen ester, List of progestogen esters, Steroidal antiandrogen and List of steroidal antiandrogens.

MPA is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. Specifically, it is the 17α-acetate ester of medroxyprogesterone or the 6α-methylated analogue of hydroxyprogesterone acetate. MPA is known chemically as 6α-methyl-17α-acetoxyprogesterone or as 6α-methyl-17α-acetoxypregn-4-ene-3,20-dione, and its generic name is a contraction of 6α-methyl-17α-hydroxyprogesterone acetate. MPA is closely related to other 17α-hydroxyprogesterone derivatives such as chlormadinone acetate, cyproterone acetate, and megestrol acetate, as well as to medrogestone and nomegestrol acetate. 9α-fluoromedroxyprogesterone acetate (FMPA), the C9α fluoro analogue of MPA and an angiogenesis inhibitor with two orders of magnitude greater potency in comparison to MPA, was investigated for the potential treatment of cancers but was never marketed.[187] [188]

History

MPA was independently discovered in 1956 by Syntex and the Upjohn Company.[10] [189] [190] It was first introduced on 18 June 1959 by Upjohn in the United States under the brand name Provera (2.5, 5, and 10 mg tablets) for the treatment of amenorrhea, metrorrhagia, and recurrent miscarriage.[191] [192] An intramuscular formulation of MPA, now known as DMPA (400 mg/mL MPA), was also introduced, under the brand name brand name Depo-Provera, in 1960 in the U.S. for the treatment of endometrial and renal cancer. MPA in combination with ethinylestradiol was introduced in 1964 by Upjohn in the U.S. under the brand name Provest (10 mg MPA and 50 μg ethinylestradiol tablets) as an oral contraceptive, but this formulation was discontinued in 1970.[193] [194] [195] This formulation was marketed by Upjohn outside of the U.S. under the brand names Provestral and Provestrol, while Cyclo-Farlutal (or Ciclofarlutal) and Nogest-S[196] were formulations available outside of the U.S. with a different dosage (5 mg MPA and 50 or 75 μg ethinylestradiol tablets).[197] [198]

Following its development in the late 1950s, DMPA was first assessed in clinical trials for use as an injectable contraceptive in 1963.[199] Upjohn sought approval of intramuscular DMPA as a long-acting contraceptive under the brand name Depo-Provera (150 mg/mL MPA) in 1967, but the application was rejected.[200] [201] However, this formulation was successfully introduced in countries outside of the United States for the first time in 1969, and was available in over 90 countries worldwide by 1992.[202] Upjohn attempted to gain FDA approval of DMPA as a contraceptive again in 1978, and yet again in 1983, but both applications failed similarly to the 1967 application. However, in 1992, the medication was finally approved by the FDA, under the brand name Depo-Provera, for use in contraception. A subcutaneous formulation of DMPA was introduced in the United States as a contraceptive under the brand name Depo-SubQ Provera 104 (104 mg/0.65 mL MPA) in December 2004, and subsequently was also approved for the treatment of endometriosis-related pelvic pain.[203]

MPA has also been marketed widely throughout the world under numerous other brand names such as Farlutal, Perlutex, and Gestapuran, among others.[204]

Society and culture

Generic names

Medroxyprogesterone acetate is the generic name of the drug and its,,, and, while medrossiprogesterone is the and médroxyprogestérone the of its free alcohol form.[205] [206] [207] [208] It is also known as 6α-methyl-17α-acetoxyprogesterone (MAP) or 6α-methyl-17α-hydroxyprogesterone acetate.

Brand names

MPA is marketed under a large number of brand names throughout the world. Its most major brand names are Provera as oral tablets and Depo-Provera as an aqueous suspension for intramuscular injection. A formulation of MPA as an aqueous suspension for subcutaneous injection is also available in the United States under the brand name Depo-SubQ Provera 104. Other brand names of MPA formulated alone include Farlutal and Sayana for clinical use and Depo-Promone, Perlutex, Promone-E, and Veramix for veterinary use. In addition to single-drug formulations, MPA is marketed in combination with the estrogens CEEs, estradiol, and estradiol valerate. Brand names of MPA in combination with CEEs as oral tablets in different countries include Prempro, Premphase, Premique, Premia, and Premelle. Brand names of MPA in combination with estradiol as oral tablets include Indivina and Tridestra.

Availability

Oral MPA and DMPA are widely available throughout the world. Oral MPA is available both alone and in combination with the estrogens CEEs, estradiol, and estradiol valerate. DMPA is registered for use as a form of birth control in more than 100 countries worldwide.[209] [210] The combination of injected MPA and estradiol cypionate is approved for use as a form of birth control in 18 countries.

United States

See also: List of progestogens available in the United States.

, MPA is available in the United States in the following formulations:[211]

It is also available in combination with an estrogen in the following formulations:

While the following formulations have been discontinued:

The state of Louisiana permits sex offenders to be given MPA.[212]

Generation

Progestins in birth control pills are sometimes grouped by generation.[213] [214] While the 19-nortestosterone progestins are consistently grouped into generations, the pregnane progestins that are or have been used in birth control pills are typically omitted from such classifications or are grouped simply as "miscellaneous" or "pregnanes". In any case, based on its date of introduction in such formulations of 1964, MPA could be considered a "first-generation" progestin.[215]

Controversy

Outside the United States

United States

There was a long, controversial history regarding the approval of DMPA by the U.S. Food and Drug Administration. The original manufacturer, Upjohn, applied repeatedly for approval. FDA advisory committees unanimously recommended approval in 1973, 1975 and 1992, as did the FDA's professional medical staff, but the FDA repeatedly denied approval. Ultimately, on 29 October 1992, the FDA approved DMPA for birth control, which had by then been used by over 30 million women since 1969 and was approved and being used by nearly 9 million women in more than 90 countries, including the United Kingdom, France, Germany, Sweden, Thailand, New Zealand and Indonesia.[222] Points in the controversy included:

Research

DMPA was studied by Upjohn for use as a progestogen-only injectable contraceptive in women at a dose of 50 mg once a month but produced poor cycle control and was not marketed for this use at this dosage.[236] A combination of DMPA and polyestradiol phosphate, an estrogen and long-lasting prodrug of estradiol, was studied in women as a combined injectable contraceptive for use by intramuscular injection once every three months.[237] [238] [239]

High-dose oral and intramuscular MPA monotherapy has been studied in the treatment of prostate cancer but was found to be inferior to monotherapy with cyproterone acetate or diethylstilbestrol.[240] [241] [242] High-dose oral MPA has been studied in combination with diethylstilbestrol and CEEs as an addition to high-dose estrogen therapy for the treatment of prostate cancer in men, but was not found to provide better effectiveness than diethylstilbestrol alone.[243]

DMPA has been studied for use as a potential male hormonal contraceptive in combination with the androgens/anabolic steroids testosterone and nandrolone (19-nortestosterone) in men.[244] However, it was never approved for this indication.

MPA was investigated by InKine Pharmaceutical, Salix Pharmaceuticals, and the University of Pennsylvania as a potential anti-inflammatory medication for the treatment of autoimmune hemolytic anemia, Crohn's disease, idiopathic thrombocytopenic purpura, and ulcerative colitis, but did not complete clinical development and was never approved for these indications.[245] [246] It was formulated as an oral medication at very high dosages, and was thought to inhibit the signaling of proinflammatory cytokines such as interleukin 6 and tumor necrosis factor alpha, with a mechanism of action that was said to be similar to that of corticosteroids. The formulation of MPA had the tentative brand names Colirest and Hematrol for these indications.

MPA has been found to be effective in the treatment of manic symptoms in women with bipolar disorder.[247]

Veterinary use

MPA has been used to reduce aggression and spraying in male cats.[248] It may be particularly useful for controlling such behaviors in neutered male cats. The medication can be administered in cats as an injection once per month.

See also

Notes and References

  1. Web site: Medroxyprogesterone Uses, Dosage & Side Effects.
  2. Web site: Product monograph brand safety updates . Health Canada . February 2024 . 24 March 2024.
  3. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH . Classification and pharmacology of progestins . Maturitas . 61 . 1–2 . 171–80 . 2008 . 19434889 . 10.1016/j.maturitas.2008.11.013 .
  4. Web site: Provera. FDA. 31 March 2018. 2015. https://web.archive.org/web/20170211092207/http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf. 11 February 2017. dead.
  5. Web site: Depo_Provera. FDA. 31 March 2018. 2016.
  6. Web site: depo-subQ Provera. FDA. 31 March 2018. 2017.
  7. Kuhl H . Pharmacology of estrogens and progestogens: influence of different routes of administration . Climacteric . 8 . Suppl 1 . 3–63 . 2005 . 16112947 . 10.1080/13697130500148875 . 24616324 .
  8. Web site: Medroxyprogesterone Acetate. The American Society of Health-System Pharmacists. 8 December 2016. live. https://web.archive.org/web/20161224100359/https://www.drugs.com/monograph/medroxyprogesterone-acetate.html. 24 December 2016.
  9. Book: Roberts SM . Introduction to Biological and Small Molecule Drug Research and Development: Chapter 12. Hormone replacement therapy. 7 May 2013. Elsevier Science. 978-0-12-806202-9. 9–. [...] medroxyprogesterone acetate, also known as Provera (discovered simultaneously by Searle and Upjohn in 1956) [..].
  10. Book: Sneader W . Drug discovery: a history . Wiley . New York . 2005 . 204 . 0-471-89980-1 . Chapter 18: Hormone analogs .
  11. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 21st list 2019 . 2019 . 10665/325771 . World Health Organization . World Health Organization . Geneva . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO . free .
  12. Book: Meikle AW . Hormone Replacement Therapy. 1 June 1999. Springer Science & Business Media. 978-1-59259-700-0. 383–.
  13. Book: Special Programme of Research, Development, and Research Training in Human Reproduction (World Health Organization). World Health Organization. Research on Reproductive Health at WHO: Biennial Report 2000-2001. 2002. World Health Organization. 978-92-4-156208-9. 17–.
  14. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  15. Web site: Medroxyprogesterone - Drug Usage Statistics . ClinCalc . 14 January 2024.
  16. Furness S, Roberts H, Marjoribanks J, Lethaby A . Hormone therapy in postmenopausal women and risk of endometrial hyperplasia . The Cochrane Database of Systematic Reviews . 8 . CD000402 . August 2012 . 2012 . 22895916 . 10.1002/14651858.CD000402.pub4 . 7039145 .
  17. Web site: Medroxyprogesterone . 2 July 2010 . 9 January 2008 . . live . https://web.archive.org/web/20100712043213/http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682470.html . 12 July 2010 .
  18. Panay N, Fenton A . Bioidentical hormones: what is all the hype about? . Climacteric . 13 . 1 . 1–3 . February 2010 . 20067429 . 10.3109/13697130903550250 . 244295 .
  19. Light SA, Holroyd S . The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia . Journal of Psychiatry & Neuroscience . 31 . 2 . 132–4 . March 2006 . 16575429 . 1413960 . live . https://web.archive.org/web/20160307005616/https://www.cma.ca/multimedia/staticContent/HTML/N0/l2/jpn/vol-31/issue-2/pdf/pg132.pdf . 7 March 2016 .
  20. Web site: The chemical knife . 22 January 2009 . dead . https://web.archive.org/web/20090107134347/http://archive.salon.com/health/feature/2000/03/01/castration/ . 7 January 2009 .
  21. Ganzina F . High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review . Tumori . 65 . 5 . 563–85 . October 1979 . 390798 . 10.1177/030089167906500507. 23378403 .
  22. Kjaer M . The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma . Cancer Treat. Rev. . 15 . 3 . 195–209 . September 1988 . 2974757 . 10.1016/0305-7372(88)90003-5.
  23. Vanderstappen D, Bonte J . New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies . Eur. J. Gynaecol. Oncol. . 13 . 2 . 113–23 . 1992 . 1534051 .
  24. Gooren L . Hormone treatment of the adult transsexual patient . Horm. Res. . 64 . Suppl 2 . 31–6 . 2005 . 16286768 . 10.1159/000087751 . 1 July 2024 . 42507159 .
  25. Book: Sachdeva A, Dutta AK . Advances in Pediatrics. 31 August 2012. JP Medical Ltd. 978-93-5025-777-7. 1202–.
  26. Book: Hammerstein J . Hair and Hair Diseases. Antiandrogens: Clinical Aspects. 1990. 827–886. 10.1007/978-3-642-74612-3_35. 978-3-642-74614-7.
  27. Book: Trussell J . 2011. Contraceptive efficacy . Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS . Contraceptive technology . 20th revised . New York . Ardent Media . 978-1-59708-004-0 . 781956734 . 779–863 . Table 26–1 = Table 3–2 Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception, and the percentage continuing use at the end of the first year. United States.
  28. Book: Trussell J . 2004 . Contraceptive Efficacy . Hatcher RA, Trussell J, Stewart FH, Nelson AL, Cates Jr W, Guest F, Kowal D . Contraceptive Technology . 18th rev. . 773–845 . New York . Ardent Media . 0-9664902-5-8.
  29. Trussell J . Contraceptive failure in the United States . Contraception . 70 . 2 . 89–96 . August 2004 . 15288211 . 10.1016/j.contraception.2004.03.009 . 3638209 .
  30. Trussell J, Hatcher RA, Cates W, Stewart FH, Kost K . A guide to interpreting contraceptive efficacy studies . Obstetrics and Gynecology . 76 . 3 Pt 2 . 558–67 . September 1990 . 2199875 .
  31. Book: Trussell J . 1994 . Contraceptive Failure Rates . Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS . Contraceptive Technology . 16th rev. . 637–688 . New York . Irvington Publishers . 0-8290-3171-5 . registration .
  32. Book: Trussell J . 1998 . Contraceptive Efficacy . Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, Kowal D . Contraceptive Technology . 17th rev. . 779–844 . New York . Ardent Media . 0-9664902-0-7 . https://archive.org/details/contraceptivetec00hatc . registration .
  33. Web site: FDA . 1998 . Guidance for Industry - Uniform Contraceptive Labeling . . 21 June 2007 . https://web.archive.org/web/20070225182414/https://www.fda.gov/cdrh/ode/contrlab.pdf . 25 February 2007 . Food and Drug Administration.
  34. Book: Trussell J . 2007 . Contraceptive Efficacy . Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D . Contraceptive Technology . 19th rev. . New York . Ardent Media . http://www.contraceptivetechnology.com/table.html . 21 June 2007 . dead . https://web.archive.org/web/20080531095926/http://www.contraceptivetechnology.com/table.html . 31 May 2008 .
  35. Trussell J, Vaughan B . Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth . Family Planning Perspectives . 31 . 2 . 64–72, 93 . 1999 . 10224544 . 10.2307/2991641 . 2991641 . live . https://web.archive.org/web/20081202020036/https://www.guttmacher.org/pubs/journals/3106499.pdf . 2 December 2008 .
  36. Westhoff C . Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety . Contraception . 68 . 2 . 75–87 . August 2003 . 12954518 . 10.1016/S0010-7824(03)00136-7 .
  37. Book: Mishell DR . 2004 . Strauss III JF, Barbieri RL . Yen and Jaffe's Reproductive Endocrinology . 5th . Elsevier Saunders . Philadelphia . 0-7216-9546-9 . 899–938 . Contraception.
  38. Kaunitz AM . Current options for injectable contraception in the United States . Seminars in Reproductive Medicine . 19 . 4 . 331–7 . December 2001 . 11727175 . 10.1055/s-2001-18641 . 39556669 .
  39. Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M . Depo Provera. Position paper on clinical use, effectiveness and side effects . The British Journal of Family Planning . 25 . 2 . 69–76 . July 1999 . 10454658 .
  40. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives . International Journal of Cancer . 49 . 2 . 186–90 . September 1991 . 1831802 . 10.1002/ijc.2910490207 . 221776781 .
  41. Book: Santen RJ . Strauss III JF, Barbieri RL . Yen and Jaffe's Reproductive Endocrinology . 5th . 2004 . Elsevier Saunders . Philadelphia . 0-7216-9546-9 . 787–809 . Endocrinology of Breast and Endometrial Cancer.
  42. Book: Bartz D, Goldberg AB . 2011 . Injectable contraceptives . Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS . Contraceptive technology . 20th revised . New York . Ardent Media . 978-1-59708-004-0 . 781956734 . 212–213 . Advantages of DMPA Injectables. 5. Reduced risk of ectopic pregnancy. Compared with women who use no contraceptive at all, women who use DMPA have a reduced risk for having an ectopic pregnancy. Although the overall risk of pregnancy and thus ectopic pregnancy is lowered by DMPA, the possibility of an ectopic pregnancy should be excluded if a woman using DMPA becomes pregnant. One study showed that 1.5% of women who got pregnant on DMPA had an ectopic pregnancy, the same ectopic rate as women who conceived while not using contraception.27.
  43. Borgatta L, Murthy A, Chuang C, Beardsley L, Burnhill MS . Pregnancies diagnosed during Depo-Provera use . Contraception . 66 . 3 . 169–72 . September 2002 . 12384205 . 10.1016/S0010-7824(02)00340-2 .
  44. O'Brien MD, Guillebaud J . September 2006 . Contraception for women with epilepsy . Epilepsia . 47 . 9 . 1419–22 . 10.1111/j.1528-1167.2006.00671.x . 16981856 . 22284176 . free.
  45. News: Increasing use of long-acting reversible contraception . Nursing Times.net . 21 October 2008 . 19 June 2009 . live . https://web.archive.org/web/20090826233650/https://www.nursingtimes.net/clinical-archive/sexual-health/increasing-use-of-long-acting-reversible-contraception-21-10-2008/ . 26 August 2009 .
  46. Web site: CG30 Long-acting reversible contraception: quick reference guide . National Institute for Health and Clinical Excellence . 19 June 2009 . dead . https://web.archive.org/web/20090920091647/http://www.nice.org.uk/nicemedia/pdf/cg030quickrefguide.pdf . 20 September 2009 .
  47. Web site: Sexual Health Ruleset . New GMS Contract Quality and Outcome Framework - Implementation Dataset and Business Rules . Primary Care Commissioning . 1 May 2009 . 19 June 2009 . live . https://web.archive.org/web/20110810074228/http://www.pcc.nhs.uk/uploads/QOF/Business%20Rules%20v14/sexual_health_ruleset_r4_v14_0.pdf . 10 August 2011 .
    Summarized at
    * Web site: Contraception - Management QOF indicators . NHS Clinical Knowledge Summaries . NHS Institute for Innovation and Improvement . 19 June 2009 .
  48. Holtorf K . The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? . Postgraduate Medicine . 121 . 1 . 73–85 . January 2009 . 19179815 . 10.3810/pgm.2009.01.1949 . 2060730 . Kent Holtorf . dead . https://web.archive.org/web/20110708075449/http://www.bobmehrpharmacies.com/images/_content/bio-identical/The%20Bioidentical%20Hormone%20Debate-%20Ken%20Holtorf%20MD.pdf . 8 July 2011 .
  49. Cirigliano M . Bioidentical hormone therapy: a review of the evidence . Journal of Women's Health . 16 . 5 . 600–31 . June 2007 . 17627398 . 10.1089/jwh.2006.0311 . dead . https://web.archive.org/web/20110106204000/http://www.solaltech.com/doctors/3/Bioidentical%20Hormone%20Therapy--%20Cirigliano.pdf . 6 January 2011 .
  50. Boothby LA, Doering PL . Bioidentical hormone therapy: a panacea that lacks supportive evidence . Current Opinion in Obstetrics and Gynecology . 20 . 4 . 400–7 . August 2008 . 18660693 . 10.1097/GCO.0b013e3283081ae9 . 22449765 .
  51. Book: Engorn B, Flerlage J . The Harriet Lane Handbook E-Book. 1 May 2014. Elsevier Health Sciences. 978-0-323-11246-8. 846–.
  52. Book: Tiziani AP . Havard's Nursing Guide to Drugs. 1 June 2013. Elsevier Health Sciences. 978-0-7295-8162-2. 989–.
  53. Book: Leidenberger FA . Klinische Endokrinologie für Frauenärzte. 17 April 2013. Springer-Verlag. 978-3-662-08110-5. 528–.
  54. Stacey, Dawn. Depo Provera: The Birth Control Shot Accessed 13 October 2009.
  55. Book: WHO . 2004 . Progestogen-only contraceptives . Medical Eligibility Criteria for Contraceptive Use . 3rd . Geneva . Reproductive Health and Research, WHO . 92-4-156266-8 . https://www.who.int/reproductive-health/publications/mec/pocs.html . World Health Organization . live . https://web.archive.org/web/20090531160312/http://www.who.int/reproductive-health/publications/mec/pocs.html . 31 May 2009.
  56. Web site: FFPRHC . 2006 . The UK Medical Eligibility Criteria for Contraceptive Use (2005/2006) . 11 January 2007 . https://web.archive.org/web/20070619230102/http://www.ffprhc.org.uk/admin/uploads/UKMEC200506.pdf . 19 June 2007 . Royal College of Obstetricians and Gynaecologists.
  57. Web site: . MedroxyPROGESTERone: Drug Information Provided by Lexi-Comp . 8 July 2010 . 1 December 2009 . live . https://web.archive.org/web/20100724182722/http://www.merck.com/mmpe/lexicomp/medroxyprogesterone.html . 24 July 2010.
  58. Book: King SR . Neurosteroids and the Nervous System . 9 November 2012 . Springer Science & Business Media . 978-1-4614-5559-2 . 45– . live . https://web.archive.org/web/20171105200514/https://books.google.com/books?id=D1fOTC6CP3kC&pg=PA45 . 5 November 2017.
  59. Web site: Pfizer . October 2004 . Depo-Provera Contraceptive Injection, US patient labeling . 21 February 2007 . dead . https://web.archive.org/web/20070206044043/http://www.pfizer.com/pfizer/download/ppi_depo_provera_contraceptive.pdf . 6 February 2007 . Pfizer .
  60. Amatayakul K, Sivasomboon B, Thanangkul O . Vitamin and trace mineral metabolism in medroxyprogesterone acetate users . Contraception . 18 . 3 . 253–69 . September 1978 . 720068 . 10.1016/s0010-7824(78)80019-5 .
  61. Book: Meyler L . Meyler's side effects of endocrine and metabolic drugs . . Amsterdam . 2009 . 281–284] . 978-0-444-53271-8 . live . https://web.archive.org/web/20141023181123/http://books.google.com/books?id=BWMeSwVwfTkC&pg=PA281 . 23 October 2014 .
  62. Exposure to DMPA in pregnancy may cause low birth weight . Progress in Human Reproduction Research . 23 . 2–3 . 1992 . 12286194 .
  63. Book: Lobo RA . Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 5 June 2007. Elsevier. 978-0-08-055309-2. 211–.
  64. Kaunitz AM . Long-acting hormonal contraception: assessing impact on bone density, weight, and mood . Int J Fertil Womens Med . 44 . 2 . 110–7 . 1999 . 10338269 . Despite the efficacy and increasing acceptability of these long-term methods, some clinicians and women are reluctant to use them because of concerns regarding reduction in bone density with DMPA, and depressive symptoms and body weight issues with both injectables and implants. Recent multicenter experience showed no increase in depressive symptoms after 1 year's DMPA use and 2 years' Norplant use, even among users with the highest mean depressive symptom scores pre-therapy..
  65. Worly BL, Gur TL, Schaffir J . The relationship between progestin hormonal contraception and depression: a systematic review . Contraception . 97. 6. 478–489. February 2018 . 29496297 . 10.1016/j.contraception.2018.01.010 . 3644828 .
  66. Westhoff C . Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety . Contraception . 68 . 2 . 75–87 . August 2003 . 12954518 . 10.1016/s0010-7824(03)00136-7. Another common patient tolerability concern reported with hormonal contraception is the effect on mood [95]. The majority of published reports indicate that DMPA does not cause depressive symptoms. In a large, 1-year, clinical trial of DMPA in 3857 US women, fewer than 2% of users reported depression [15]. Other reports in various settings, including a private practice [96], adolescent clinics [97,98], a psychiatric hospital [99] and inner-city family-planning clinics [100,101], have not found an adverse effect of DMPA on depression. [...] Using a variety of objective indices for depressive symptoms, the overall data for both OCs and DMPA are supportive that these agents have no significant effect on mood. Although history of mood symptoms prior to OC use may predispose a subgroup of women to negative mood changes, the data for DMPA suggest that even women who have depressive symptoms prior to treatment can tolerate therapy with no exacerbation of these symptoms..
  67. Bakry S, Merhi ZO, Scalise TJ, Mahmoud MS, Fadiel A, Naftolin F . Depot-medroxyprogesterone acetate: an update . Arch. Gynecol. Obstet. . 278 . 1 . 1–12 . July 2008 . 18470526 . 10.1007/s00404-007-0497-z . 11340062 .
  68. Westhoff C, Truman C, Kalmuss D, Cushman L, Davidson A, Rulin M, Heartwell S . Depressive symptoms and Depo-Provera . Contraception . 57 . 4 . 237–40 . April 1998 . 9649914 . 10.1016/s0010-7824(98)00024-9. free .
  69. Book: Aronson JK . Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. 15 October 2015. Elsevier Science. 978-0-444-53716-4. 2–. Perhaps surprisingly, a consensus seems to be emerging that depot medroxyprogesterone acetate implants do not in fact result in an increase in the incidence of depression or in the severity of pre-existing depression, even after 1 or 2 years, nor do they cause significant weight gain..
  70. Book: Fink G, Pfaff DW, Levine J . Handbook of Neuroendocrinology. 31 August 2011. Academic Press. 978-0-12-378554-1. 564–.
  71. Book: Ryden J . Practical Gynecology: A Guide for the Primary Care Physician. 2009. ACP Press. 978-1-934465-05-9. 379–.
  72. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA . Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial . JAMA . 287 . 5 . 591–7 . February 2002 . 11829697 . 10.1001/jama.287.5.591 . free .
  73. Wiegratz I, Kuhl H . Progestogen therapies: differences in clinical effects? . Trends Endocrinol. Metab. . 15 . 6 . 277–85 . August 2004 . 15358281 . 10.1016/j.tem.2004.06.006 . 35891204 .
  74. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial . JAMA . 288 . 3 . 321–33 . July 2002 . 12117397 . 10.1001/jama.288.3.321 . 20149703 .
  75. Prentice RL, Anderson GL . The women's health initiative: lessons learned . Annual Review of Public Health . 29 . 131–50 . 2008 . 18348708 . 10.1146/annurev.publhealth.29.020907.090947 . free .
  76. Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L . Hormone therapy prescribing patterns in the United States . Obstetrics and Gynecology . 104 . 5 Pt 1 . 1042–50 . November 2004 . 15516400 . 10.1097/01.AOG.0000143826.38439.af . 31593637 .
  77. Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H . Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy . VASA. Zeitschrift für Gefässkrankheiten . 47 . 6 . 441–450 . October 2018 . 30008249 . 10.1024/0301-1526/a000726 . 51628832 .
  78. DeLoughery TG . Estrogen and thrombosis: controversies and common sense . Reviews in Endocrine & Metabolic Disorders . 12 . 2 . 77–84 . June 2011 . 21559819 . 10.1007/s11154-011-9178-0 . 28053690 .
  79. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI . Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis . BMJ . 345 . aug07 2 . e4944 . August 2012 . 22872710 . 3413580 . 10.1136/bmj.e4944 .
  80. Tepper NK, Jeng G, Curtis KM, Boutot ME, Boulet SL, Whiteman MK . Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum . Obstetrics and Gynecology . 133 . 3 . 533–540 . March 2019 . 30741807 . 10.1097/AOG.0000000000003135 . free . 10983016 .
  81. van Hylckama Vlieg A, Middeldorp S . Hormone therapies and venous thromboembolism: where are we now? . Journal of Thrombosis and Haemostasis . 9 . 2 . 257–266 . February 2011 . 21114755 . 10.1111/j.1538-7836.2010.04148.x . 32394836 . free .
  82. Benagiano G, Primiero FM . Long acting contraceptives. Present status . Drugs . 25 . 6 . 570–609 . June 1983 . 6223801 . 10.2165/00003495-198325060-00003 . 45898359 .
  83. Rott H . Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen . Hamostaseologie . 39 . 1 . 42–48 . February 2019 . 30669160 . 10.1055/s-0039-1677806 . 58947063 .
  84. Scarabin PY . Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis . Climacteric . 21 . 4 . 341–345 . August 2018 . 29570359 . 10.1080/13697137.2018.1446931 . 4229701 .
  85. Sitruk-Ware R, Nath A . Metabolic effects of contraceptive steroids . Reviews in Endocrine & Metabolic Disorders . 12 . 2 . 63–75 . June 2011 . 21538049 . 10.1007/s11154-011-9182-4 . 23760705 .
  86. Web site: Depot medroxyprogesterone acetate and bone effects. Committee Opinion #602 . June 2014 . 3 May 2015 . live . https://web.archive.org/web/20150430112715/http://www.acog.org/ . 30 April 2015.
  87. Web site: FDA . Food and Drug Administration . 17 November 2004 . Black Box Warning Added Concerning Long-Term Use of Depo-Provera Contraceptive Injection . . 12 May 2006 . https://web.archive.org/web/20051221195621/https://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html . 21 December 2005.
  88. Nelson AL . DMPA: battered and bruised but still needed and used in the USA. Expert Review of Obstetrics & Gynecology. 5. 6. 2014. 673–686. 1747-4108. 10.1586/eog.10.60.
  89. Web site: World Health Organization . World Health Organization . September 2005 . Hormonal contraception and bone health . Family Planning . 12 May 2006 . dead . https://web.archive.org/web/20060514022320/http://www.who.int/reproductive-health/family_planning/bone_health.html . 14 May 2006 .
  90. Curtis KM, Martins SL . Progestogen-only contraception and bone mineral density: a systematic review . Contraception . 73 . 5 . 470–87 . May 2006 . 16627031 . 10.1016/j.contraception.2005.12.010 .
  91. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR . Recovery of bone density in women who stop using medroxyprogesterone acetate . BMJ . 308 . 6923 . 247–8 . January 1994 . 8111260 . 2539337 . 10.1136/bmj.308.6923.247 .
  92. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM . Injectable hormone contraception and bone density: results from a prospective study . Epidemiology . 13 . 5 . 581–7 . September 2002 . 12192229 . 10.1097/00001648-200209000-00015 . free .
  93. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM . Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception . Archives of Pediatrics & Adolescent Medicine . 159 . 2 . 139–44 . February 2005 . 15699307 . 10.1001/archpedi.159.2.139 . free .
  94. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR . The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women . Clinical Endocrinology . 49 . 5 . 615–8 . November 1998 . 10197077 . 10.1046/j.1365-2265.1998.00582.x . 22565912 .
  95. Cundy T, Cornish J, Roberts H, Reid IR . Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception . American Journal of Obstetrics and Gynecology . 186 . 5 . 978–83 . May 2002 . 12015524 . 10.1067/mob.2002.122420 .
  96. Walsh JS, Eastell R, Peel NF . Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density . Fertility and Sterility . 93 . 3 . 697–701 . February 2010 . 19013564 . 10.1016/j.fertnstert.2008.10.004 . free .
  97. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects . Obstetrics and Gynecology . 112 . 3 . 727–30 . September 2008 . 18757687 . 10.1097/AOG.0b013e318188d1ec . American College of Obstetricians Gynecologists Committee on Gynecologic Practice . free .
  98. Polis CB, Phillips SJ, Curtis KM, Westreich DJ, Steyn PS, Raymond E, Hannaford P, Turner AN . Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence . Contraception . 90 . 4 . 360–90 . October 2014 . 25183264 . 10.1016/j.contraception.2014.07.009 . free . 2164/4151 . free .
  99. Web site: WHO Department of Reproductive Health and Research. 16 February 2012. Technical Statement: Hormonal contraception and HIV. Geneva. World Health Organization. dead. https://web.archive.org/web/20150130063224/http://www.who.int/reproductivehealth/publications/family_planning/rhr_12_8/en/. 30 January 2015.
  100. Web site: WHO Department of Reproductive Health and Research. 23 July 2014. 2014 Guidance Statement: Hormonal contraceptive methods for women at high risk of HIV and living with HIV. Geneva. World Health Organization. dead. https://web.archive.org/web/20150130063143/http://apps.who.int/iris/bitstream/10665/128537/1/WHO_RHR_14.24_eng.pdf. 30 January 2015.
  101. Web site: AVAC. 27 January 2015. News from the HC-HIV front: it's raining meta (analyses)!. New York. AIDS Vaccine Advocacy Coalition. live. https://web.archive.org/web/20150130053427/http://www.avac.org/blog/news-hc-hiv-front. 30 January 2015.
  102. Ralph LJ, McCoy SI, Shiu K, Padian NS . Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies . The Lancet. Infectious Diseases . 15 . 2 . 181–9 . February 2015 . 25578825 . 10.1016/S1473-3099(14)71052-7 . 4526270.
  103. Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JH, Stalter R, Low N . Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis . PLOS Medicine . 12 . 1 . e1001778 . January 2015 . 25612136 . 4303292 . 10.1371/journal.pmed.1001778 . free .
  104. Web site: Faculty of Sexual Reproductive Healthcare. January 2015. CEU Statement: Depot medroxyprogesterone acetate (DMPA, Depo-Provera) and risk of HIV acquisition. London. Royal College of Obstetricians and Gynaecologists. dead. https://web.archive.org/web/20150130073139/http://www.fsrh.org/pdfs/CEUStatementDMPAandHIV.pdf. 30 January 2015.
  105. Brind J, Condly SJ, Mosher SW, Morse AR, Kimball J . Risk of HIV Infection in Depot-Medroxyprogesterone Acetate (DMPA) Users: A Systematic Review and Meta-analysis . Issues Law Med . 30 . 2 . 129–39 . 2015 . 26710371 .
  106. ECHO Trial Consortium . HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial . The Lancet . 394. 10195. 303–313. 13 June 2019 . 10.1016/S0140-6736(19)31288-7 . 31204114 . free . 6675739.
  107. Dahlberg K . Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user . International Journal of Gynaecology and Obstetrics . 20 . 1 . 43–8 . February 1982 . 6126406 . 10.1016/0020-7292(82)90044-3 . 8295162 .
  108. Pardthaisong T, Yenchit C, Gray R . The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation . Contraception . 45 . 4 . 313–24 . April 1992 . 1387602 . 10.1016/0010-7824(92)90053-V .
  109. Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P . A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate . Cancer Treat Rep . 62 . 4 . 499–504 . April 1978 . 350387 .
  110. Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF . Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial . Cancer . 82 . 3 . 553–60 . February 1998 . 9452274 . 10.1002/(sici)1097-0142(19980201)82:3<553::aid-cncr18>3.0.co;2-0. free .
  111. Book: World Health Organization . Residues of Some Veterinary Drugs in Animals and Food: Monographs Prepared by the Sixty-second Meeting of the Joint FAO/WHO Expert Committee on Food Additives, Rome, 4-12 February 2004 . 2004 . Food & Agriculture Org. . 978-92-5-105195-5 . 49 . live . https://web.archive.org/web/20140617202257/http://books.google.com/books?id=4cmezxyAHGUC&pg=PA49 . 17 June 2014 .
  112. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM . Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone . Molecular Endocrinology . 13 . 3 . 440–54 . March 1999 . 10077001 . 10.1210/mend.13.3.0255 . free .
  113. Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD . Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells . Molecular and Cellular Endocrinology . 154 . 1–2 . 11–20 . August 1999 . 10509795 . 10.1016/S0303-7207(99)00109-4 . 25584803 .
  114. Pullen MA, Laping N, Edwards R, Bray J . Determination of conformational changes in the progesterone receptor using ELISA-like assays . Steroids . 71 . 9 . 792–8 . September 2006 . 16784762 . 10.1016/j.steroids.2006.05.009 . 24703323 .
  115. Wikström A, Green B, Johansson ED . The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses . Acta Obstetricia et Gynecologica Scandinavica . 63 . 2 . 163–8 . 1984 . 6233840 . 10.3109/00016348409154654 . 45767999 .
  116. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH . Classification and pharmacology of progestins . Maturitas . 46 . Suppl 1 . S7–S16 . December 2003 . 14670641 . 10.1016/j.maturitas.2003.09.014 .
  117. Book: Glasier A . Anna Glasier . DeGroot LJ, Jameson JL . Endocrinology . 5th . 2006 . Elsevier Saunders . Philadelphia . 978-0-7216-0376-6 . 2993–3003 . Contraception .
  118. Book: Loose DS, Stancel GM . Loose DS, Stancel GM . 2006 . Estrogens and Progestins . Goodman & Gilman's The Pharmacological Basis of Therapeutics . 11th . 1541–1571 . New York . McGraw-Hill . 0-07-142280-3.
  119. Book: Hatcher RA . 2004 . Depo-Provera Injections, Implants, and Progestin-Only Pills (Minipills) . Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, Kowal D . Contraceptive Technology . 18th rev. . 461–494 . New York . Ardent Media . 0-9664902-5-8.
  120. Book: Speroff L, Darney PD . 2005 . Injectable Contraception . A Clinical Guide for Contraception . 4th . 201–220 . Philadelphia . Lippincott Williams & Wilkins . 0-7817-6488-2 .
  121. Rivera R, Yacobson I, Grimes D . The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices . American Journal of Obstetrics and Gynecology . 181 . 5 Pt 1 . 1263–9 . November 1999 . 10561657 . 10.1016/S0002-9378(99)70120-1 .
  122. Kuhl H . Pharmacology of Progestogens . J Reproduktionsmed Endokrinol . 2011 . 8 . 1 . 157–177 . live . https://web.archive.org/web/20161011060809/http://www.kup.at/kup/pdf/10168.pdf . 11 October 2016 .
  123. Book: Fritz MA, Speroff L . Clinical Gynecologic Endocrinology and Infertility . 28 March 2012 . Lippincott Williams & Wilkins . 978-1-4511-4847-3 . 761– .
  124. Book: Genazzani AR . Frontiers in Gynecologic and Obstetric Investigation . 15 January 1993 . Taylor & Francis . 978-1-85070-486-7 . 320 . live . https://web.archive.org/web/20160520164420/https://books.google.com/books?id=vNZ8Xb8lDF4C&pg=PA320 . 20 May 2016 .
  125. Poulin R, Baker D, Poirier D, Labrie F . Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells . Breast Cancer Research and Treatment . 13 . 2 . 161–72 . March 1989 . 2525057 . 10.1007/bf01806528 . 26116247 .
  126. Brady BM, Anderson RA, Kinniburgh D, Baird DT . Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male . Clinical Endocrinology . 58 . 4 . 506–12 . April 2003 . 12641635 . 10.1046/j.1365-2265.2003.01751.x . 12567639 . free .
  127. Book: Saleh FM, Grudzinskas AJ, Bradford JM . Sex Offenders: Identification, Risk Assessment, Treatment, and Legal Issues . 11 February 2009 . Oxford University Press . 978-0-19-517704-6 . 44 . live . https://web.archive.org/web/20140617204821/http://books.google.com/books?id=K2Tpk3qHkwcC&pg=PA44 . 17 June 2014 .
  128. Book: WHO Model Formulary 2008 . 2009 . 978-92-4-154765-9 . ((World Health Organization)) . Stuart MC, Kouimtzi M, Hill SR . 10665/44053 . World Health Organization . World Health Organization . 368 .
  129. Lothstein LM . Antiandrogen treatment for sexual disorders: Guidelines for establishing a standard of care. Sexual Addiction & Compulsivity. 3. 4. 1996. 313–331. 1072-0162. 10.1080/10720169608400122.
  130. Kravitz HM, Haywood TW, Kelly J, Liles S, Cavanaugh JL . Medroxyprogesterone and paraphiles: do testosterone levels matter? . The Bulletin of the American Academy of Psychiatry and the Law . 24 . 1 . 73–83 . 1996 . 8891323 .
  131. Novak E, Hendrix JW, Chen TT, Seckman CE, Royer GL, Pochi PE . Sebum production and plasma testosterone levels in man after high-dose medroxyprogesterone acetate treatment and androgen administration . Acta Endocrinologica . 95 . 2 . 265–270 . October 1980 . 6449127 . 10.1530/acta.0.0950265 .
  132. Kirschner MA, Schneider G . Suppression of the pituitary-Leydig cell axis and sebum production in normal men by medroxyprogesterone acetate (provera) . Acta Endocrinologica . 69 . 2 . 385–393 . February 1972 . 5066846 . 10.1530/acta.0.0690385 .
  133. Asscheman H, Gooren LJ . Hormone Treatment in Transsexuals. Journal of Psychology & Human Sexuality. 5. 4. 1993. 39–54. 0890-7064. 10.1300/J056v05n04_03. 144580633 .
  134. Meriggiola MC, Gava G . Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen . Clinical Endocrinology . 83 . 5 . 607–615 . November 2015 . 25692882 . 10.1111/cen.12754 . 39706760 . 11585/541921 .
  135. Gooren LJ, Giltay EJ, Bunck MC . Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience . The Journal of Clinical Endocrinology and Metabolism . 93 . 1 . 19–25 . January 2008 . 17986639 . 10.1210/jc.2007-1809 . free .
  136. Web site: Deutsch M . Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People . 17 June 2016 . 2nd . Center of Excellence for Transgender Health . University of California, San Francisco . 28 .
  137. Web site: Dahl M, Feldman JL, Goldberg J, Jaberi A . Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines . . 2015 . 15 August 2018 . 16 August 2018 . https://web.archive.org/web/20180816030033/http://www.phsa.ca/transcarebc/Documents/HealthProf/BC-Trans-Adult-Endocrine-Guidelines-2015.pdf . dead .
  138. Leinung MC, Feustel PJ, Joseph J . Hormonal Treatment of Transgender Women with Oral Estradiol . Transgender Health . 3 . 1 . 74–81 . 2018 . 29756046 . 5944393 . 10.1089/trgh.2017.0035 .
  139. Onu PE . Depot medroxyprogesterone in the management of benign prostatic hyperplasia . European Urology . 28 . 3 . 229–235 . 1995 . 8536777 . 10.1159/000475056 .
  140. Meyer WJ, Walker PA, Emory LE, Smith ER . Physical, metabolic, and hormonal effects on men of long-term therapy with medroxyprogesterone acetate . Fertility and Sterility . 43 . 1 . 102–109 . January 1985 . 3155506 . 10.1016/S0015-0282(16)48326-3 . free .
  141. Birrell SN, Hall RE, Tilley WD . Role of the androgen receptor in human breast cancer . Journal of Mammary Gland Biology and Neoplasia . 3 . 1 . 95–103 . January 1998 . 10819508 . 10.1023/A:1018730519839 . 12044431 .
  142. Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD . Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate . Cancer Research . 65 . 18 . 8487–96 . September 2005 . 16166329 . 10.1158/0008-5472.CAN-04-3077 . free .
  143. Book: Rees MC, Hope S, Ravnikar V . The Abnormal Menstrual Cycle . 12 August 2005 . Taylor & Francis . 978-1-84214-212-7 . 213 . live . https://web.archive.org/web/20131231191143/http://books.google.com/books?id=B6eFjomeMFcC&pg=PA213 . 31 December 2013 .
  144. Book: Aronson JK . Jeffrey Aronson . Meyler's Side Effects of Endocrine and Metabolic Drugs . 20 January 2009 . Elsevier . 978-0-444-53271-8 . 283 . live . https://web.archive.org/web/20131231191208/http://books.google.com/books?id=BWMeSwVwfTkC&pg=PA283 . 31 December 2013 .
  145. Ettinger B, Golditch IM . Medroxyprogesterone acetate for the evaluation of hypertestosteronism in hirsute women . Fertility and Sterility . 28 . 12 . 1285–8 . December 1977 . 590535 . 10.1016/S0015-0282(16)42970-5. free .
  146. Correa de Oliveira RF, Novaes LP, Lima MB, Rodrigues J, Franco S, Khenaifes AI, Francalanci CP . A new treatment for hirsutism . Annals of Internal Medicine . 83 . 6 . 817–9 . December 1975 . 1200527 . 10.7326/0003-4819-83-6-817 .
  147. Richman RA, Underwood LE, French FS, Van Wyk JJ . Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity . The Journal of Pediatrics . 79 . 6 . 963–71 . December 1971 . 4332067 . 10.1016/s0022-3476(71)80191-9 .
  148. Luciano. A. A.. Endometriosis—the role of medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology. 12. sup2. 1992. S38–S44. 0144-3615. 10.3109/01443619209045611.
  149. Nachtigall LE, Raju U, Banerjee S, Wan L, Levitz M . Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels . Menopause . 7 . 4 . 243–250 . 2000 . 10914617 . 10.1097/00042192-200007040-00006 . 3076514 .
  150. Lundgren S, Lønning PE, Utaaker E, Aakvaag A, Kvinnsland S . Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings . Journal of Steroid Biochemistry . 36 . 1–2 . 99–104 . June 1990 . 2362454 . 10.1016/0022-4731(90)90118-c .
  151. Lundgren S, Lønning PE . Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin . Journal of Steroid Biochemistry . 36 . 1–2 . 105–109 . June 1990 . 2141886 . 10.1016/0022-4731(90)90119-d .
  152. Tomić R, Ljungberg B, Damber JE . Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma . Scandinavian Journal of Urology and Nephrology . 22 . 1 . 15–18 . 1988 . 2968646 . 10.1080/00365599.1988.11690377 .
  153. Book: Dangerous Sex Offenders: A Task Force Report of the American Psychiatric Association. 1999. American Psychiatric Pub. 978-0-89042-280-9. 112–144.
  154. Merrin PK, Alexander WD . Cushing's syndrome induced by medroxyprogesterone . BMJ . 301 . 6747 . 345 . August 1990 . 2144198 . 1663616 . 10.1136/bmj.301.6747.345-a .
  155. Ishida Y, Ishida Y, Heersche JN . Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis . Osteoporos Int . 13 . 8 . 601–5 . August 2002 . 12181616 . 10.1007/s001980200080 . 23343761 .
  156. Sunde A, Rosness PA, Eik-Nes KB . Effects in vitro of medroxyprogesterone acetate on steroid metabolizing enzymes in the rat: selective inhibition of 3 alpha-hydroxysteroid oxidoreductase activity . Journal of Steroid Biochemistry . 17 . 2 . 197–203 . August 1982 . 6213817 . 10.1016/0022-4731(82)90122-4 .
  157. Penning TM, Sharp RB, Krieger NR . Purification and properties of 3 alpha-hydroxysteroid dehydrogenase from rat brain cytosol. Inhibition by nonsteroidal anti-inflammatory drugs and progestins . The Journal of Biological Chemistry . 260 . 28 . 15266–72 . December 1985 . 10.1016/S0021-9258(18)95730-3 . 2933398 . free .
  158. Pazol K, Wilson ME, Wallen K . Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques . The Journal of Clinical Endocrinology and Metabolism . 89 . 6 . 2998–3006 . June 2004 . 15181090 . 1440328 . 10.1210/jc.2003-032086 .
  159. Meyer L, Venard C, Schaeffer V, Patte-Mensah C, Mensah-Nyagan AG . The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury . Neurobiology of Disease . 30 . 1 . 30–41 . April 2008 . 18291663 . 10.1016/j.nbd.2007.12.001 . 5830825 .
  160. Mellon SH, Griffin LD . Neurosteroids: biochemistry and clinical significance . Trends in Endocrinology and Metabolism . 13 . 1 . 35–43 . 2002 . 11750861 . 10.1016/s1043-2760(01)00503-3 . 11605131 .
  161. Lee TC, Miller WL, Auchus RJ . Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes . The Journal of Clinical Endocrinology and Metabolism . 84 . 6 . 2104–10 . June 1999 . 10372718 . 10.1210/jcem.84.6.5646 . free .
  162. Söderpalm AH, Lindsey S, Purdy RH, Hauger R, Wit de H . Administration of progesterone produces mild sedative-like effects in men and women . Psychoneuroendocrinology . 29 . 3 . 339–54 . April 2004 . 14644065 . 10.1016/s0306-4530(03)00033-7 . 21796848 .
  163. McAuley JW, Kroboth PD, Stiff DD, Reynolds IJ . Modulation of [3H]flunitrazepam binding by natural and synthetic progestational agents . Pharmacology Biochemistry and Behavior . 45 . 1 . 77–83 . May 1993 . 8516376 . 10.1016/0091-3057(93)90089-c . 42764270 .
  164. Book: Weizman A . Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders: Novel Strategies for Research and Treatment . 1 February 2008 . Springer Science & Business Media . 978-1-4020-6854-6 . 104, 107, 112 .
  165. Muss HB, Cruz JM . High-dose progestin therapy for metastatic breast cancer . Annals of Oncology . 3 . Suppl 3 . 15–20 . August 1992 . 1390312 . 10.1093/annonc/3.suppl_3.S15 . free .
  166. Book: Hofbauer KG, Anker SD, Inui A, Nicholson JR. Pharmacotherapy of Cachexia. 22 December 2005. CRC Press. 978-1-4200-4895-7. 292–. Medroxyprogesterone [acetate] has similarly been shown to increase appetite and food intake with stabilization of body weight at a dose of 1000 mg (500 mg twice daily).13 Although the drug may be used at 500 to 4000 mg daily, side effects increase above oral doses of 1000 mg daily.16.
  167. Book: Doyle D, Hanks G, Cherny NI . Oxford Textbook Of Palliative Medicine . 3 February 2005 . Oxford University Press . 978-0-19-856698-4 . 553 . live . https://web.archive.org/web/20130618070049/http://books.google.com/books?id=1n93PGjL0IMC&pg=PA553 . 18 June 2013 .
  168. Neubauer H, Ma Q, Zhou J, Yu Q, Ruan X, Seeger H, Fehm T, Mueck AO . Possible role of PGRMC1 in breast cancer development . Climacteric . 16 . 5 . 509–13 . October 2013 . 23758160 . 10.3109/13697137.2013.800038 . 29808177 .
  169. Trabert B, Sherman ME, Kannan N, Stanczyk FZ . Progesterone and breast cancer . Endocr. Rev. . 41. 2. 320–344. September 2019 . 31512725 . 10.1210/endrev/bnz001 . 7156851 .
  170. Stanczyk FZ, Bhavnani BR . Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? . The Journal of Steroid Biochemistry and Molecular Biology . 142 . 30–38 . July 2014 . 24291402 . 10.1016/j.jsbmb.2013.11.011 . 22731802 .
  171. Victor A, Johansson ED . Pharmacokinetic observations on medroxyprogesterone acetate administered orally and intravaginally . Contraception . 14 . 3 . 319–329 . September 1976 . 975821 . 10.1016/0010-7824(76)90099-8 .
  172. Hiroi M, Stanczyk FZ, Goebelsmann U, Brenner PF, Lumkin ME, Mishell DR . Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration . Steroids . 26 . 3 . 373–386 . September 1975 . 1198624 . 10.1016/0039-128X(75)90082-3 . 24777672 .
  173. Svensson LO, Johnson SH, Olsson SE . Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil, Trisequence/Provera and Divina. A randomized, single-blind, triple cross-over bioavailability study in menopausal women . Maturitas . 18 . 3 . 229–238 . March 1994 . 8015506 . 10.1016/0378-5122(94)90129-5 .
  174. Järvinen A, Kainulainen P, Nissilä M, Nikkanen H, Kela M . Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women . Maturitas . 47 . 3 . 209–217 . March 2004 . 15036491 . 10.1016/j.maturitas.2003.01.001 .
  175. Web site: Medroxyprogesterone Acetate - Drug Summary . Prescribers' Digital Reference (PDR) . ConnectiveRx . https://web.archive.org/web/20181007065946/https://www.pdr.net/drug-summary/Provera-medroxyprogesterone-acetate-1015 . 17 June 2019 . 7 October 2018 . When needed, tablets may be administered sublingually†; absorption is adequate by this route..
  176. Sutton FD, Zwillich CW, Creagh CE, Pierson DJ, Weil JV . Progesterone for outpatient treatment of Pickwickian syndrome . Annals of Internal Medicine . 83 . 4 . 476–479 . October 1975 . 1101759 . 10.7326/0003-4819-83-4-476 . The sublingual route was chosen to avoid any irregular absorption that might result from simultaneous food intake. .
  177. Jain J, Kwan D, Forcier M . Medroxyprogesterone Acetate in Gender-Affirming Therapy for Transwomen: Results From a Retrospective Study . The Journal of Clinical Endocrinology and Metabolism . 104 . 11 . 5148–5156 . November 2019 . 31127826 . 10.1210/jc.2018-02253 . free .
  178. van Hoogdalem EJ, de Boer AG, Breimer DD . Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions . Clinical Pharmacokinetics . 21 . 2 . 110–128 . August 1991 . 1884566 . 10.2165/00003088-199121020-00003 . 11720029 .
  179. Mishell DR . Pharmacokinetics of depot medroxyprogesterone acetate contraception . The Journal of Reproductive Medicine . 41 . 5 Suppl . 381–390 . May 1996 . 8725700 .
  180. Sang GW . Pharmacodynamic effects of once-a-month combined injectable contraceptives . Contraception . 49 . 4 . 361–385 . April 1994 . 8013220 . 10.1016/0010-7824(94)90033-7 .
  181. Garza-Flores J, Hall PE, Perez-Palacios G . Long-acting hormonal contraceptives for women . The Journal of Steroid Biochemistry and Molecular Biology . 40 . 4–6 . 697–704 . 1991 . 1958567 . 10.1016/0960-0760(91)90293-e . 26021562 .
  182. Gabelnick HL, Hall PE . Long-acting methods for fertility regulation. Journal of Controlled Release. 6. 1. 1987. 387–394. 0168-3659. 10.1016/0168-3659(87)90092-7.
  183. Antal EJ, Dick CF, Wright III CE, Welshman IR, Block EM . Comparative bioavailability of two medroxyprogesterone acetate suspensions. International Journal of Pharmaceutics. 54. 1. 1989. 33–39. 0378-5173. 10.1016/0378-5173(89)90162-2.
  184. Ishihara M, Kirdani Y, Osawa Y, Sandberg AA . The metabolic fate of medroxyprogesterone acetate in the baboon . Journal of Steroid Biochemistry . 7 . 1 . 65–70 . January 1976 . 1271819 . 10.1016/0022-4731(76)90167-9 .
  185. Stanczyk FZ, Bhavnani BR . Reprint of "Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?" . J. Steroid Biochem. Mol. Biol. . 153 . 151–9 . September 2015 . 26291834 . 10.1016/j.jsbmb.2015.08.013 . 23985966 .
  186. Book: DeVita VT, Lawrence TS, Rosenberg SA . DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 7 January 2015. Wolters Kluwer Health. 978-1-4698-9455-3. 1149–.
  187. Ademuyiwa FO, Miller KD . Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer . Clin. Breast Cancer . 8 . Suppl 4 . S151–6 . December 2008 . 19158035 . 10.3816/CBC.2008.s.011.
  188. Web site: FMPA - AdisInsight. adisinsight.springer.com.
  189. FR . 1295307 . Procédé de préparation de dérivés cyclopentano-phénanthréniques . 8 June 1962 . 8 September 1956 . Syntex SA .
  190. US . 3377364 . granted . 6-methyl-17alpha-hydroxyprogesterone, the lower fatty acid 17-acylates and methods for producing the same . 9 April 1968 . 23 November 1956 . Spero G . Upjohn Company .
  191. Green W . Odyssey of Depo-Provera: Contraceptives, Carcinogenic Drugs, and Risk-Management Analyses . Food Drug Cosmetic Law Journal . 1987 . 42 . 567–587 . Chicago . Depo-Provera is a drug, manufactured by The Upjohn Co., whose active ingredient is medroxyprogesterone acetate (MPA). FDA first approved the drug in 1959 to treat amenorrhea,5 irregular uterine bleeding, and threatened and habitual abortion..
  192. Book: Hartmann KE, Jerome RN, Lindegren ML, Potter SA, Shields TC, Surawicz TS, Andrews JC . Primary Care Management of Abnormal Uterine Bleeding . Labeled Indications for Drugs Included in Review . 2013 . Agency for Healthcare Research and Quality (US) . 23617013 .
  193. Book: Gelijns A . Innovation in Clinical Practice: The Dynamics of Medical Technology Development . 1991 . National Academies. 167–. NAP:13513.
  194. Book: William Andrew Publishing. Pharmaceutical Manufacturing Encyclopedia. 22 October 2013. Elsevier. 978-0-8155-1856-3. 1501–.
  195. Book: Blum RW . Adolescent Health Care: Clinical Issues . 22 October 2013 . Elsevier Science . 978-1-4832-7738-7 . 216–.
  196. Book: Population/fertility control thesaurus . 1976 . Kolbe HK . Population Information Program, Science Communication Division, Dept. of Medical and Public Affairs, George Washington University . live . https://web.archive.org/web/20161009213403/http://pdf.usaid.gov/pdf_docs/pnaap426.pdf . 9 October 2016.
  197. Book: Bolivar De Lee J . The ... Year Book of Obstetrics and Gynecology. 1966. Year Book Publishers. 339. One of these is medroxyprogesterone acetate, which is sold in the United States by Upjohn as Provest, and is obtainable abroad as Provestral, Provestrol, Cyclo-Farlutal, and the more frankly suggestive Nogest..
  198. Book: Fínkelstein M . Research on Steroids. 1966. Pergamon. 469, 542.
  199. Book: Li C . Breast Cancer Epidemiology. 11 November 2009. Springer Science & Business Media. 978-1-4419-0685-4. 110–.
  200. Book: Levitt JI . Black Women and International Law: Deliberate Interactions, Movements and Actions . 30 April 2015. Cambridge University Press. 978-1-316-29840-4. 230–231.
  201. Book: Documentation on Women's Concerns. January 1998. Library and Documentation Centre, All India Association for Christian Higher Education . Upjohn meanwhile, had been repeatedly seeking FDA approval for use of DMPA as a contraceptive, but applications were rejected in 1967, 1978 and yet again in 1983, [...].
  202. Book: Nadakavukaren A . Our Global Environment: A Health Perspective, Seventh Edition. 28 February 2011. Waveland Press. 978-1-4786-0976-6. 63–.
  203. Book: Shoupe D, Mishell DR . The Handbook of Contraception: A Guide for Practical Management. 28 September 2015. Humana Press. 978-3-319-20185-6. 126–.
  204. Book: Index Nominum 2000: International Drug Directory. January 2000. Taylor & Francis. 978-3-88763-075-1. 638–. live. https://web.archive.org/web/20130619010022/http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA638. 19 June 2013.
  205. Book: Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 657. live. https://web.archive.org/web/20171105200514/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA187. 5 November 2017.
  206. Book: Sweetman, Sean C. . Sex hormones and their modulators . Martindale: The Complete Drug Reference . 36th . 2009 . 2113–2114 . Pharmaceutical Press . London. 978-0-85369-840-1. https://www.medicinescomplete.com/mc/martindale/2009/9062-p.htm.
  207. Book: Morton IK, Hall JM . Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 31 October 1999. Springer Science & Business Media. 978-0-7514-0499-9. 173–.
  208. Web site: Medroxyprogesterone Uses, Dosage & Side Effects. Drugs.com.
  209. Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S . Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control . World J Pharm Pharm Sci . 3 . 10 . 364–392 . 2014 . 2278-4357 . 2 August 2018 . https://web.archive.org/web/20170810000242/http://www.wjpps.com/download/article/1412071798.pdf . 10 August 2017 . dead .
  210. Book: Gunasheela S . Practical Management of Gynecological Problems. 14 March 2011. JP Medical Ltd. 978-93-5025-240-6. 39–.
  211. Web site: Drugs@FDA: FDA Approved Drug Products . United States Food and Drug Administration . 31 March 2018 . live . https://web.archive.org/web/20161116164727/http://www.accessdata.fda.gov/scripts/cder/daf/ . 16 November 2016 .
  212. Web site: §43.6. Administration of medroxyprogesterone acetate (MPA) to certain sex offenders. Louisiana State Legislature. Louisiana Revised Statutes. 8 July 2019. 15 November 2019. https://web.archive.org/web/20191115193434/http://legis.la.gov/legis/Law.aspx?d=508441. dead.
  213. Book: Unzeitig V, van Lunsen RH . Contraceptive Choices and Realities: Proceedings of the 5th Congress of the European Society of Contraception . 15 February 2000. CRC Press. 978-1-85070-067-8. 73–.
  214. Book: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. World Health Organization. International Agency for Research on Cancer. Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. 2007. World Health Organization. 978-92-832-1291-1. 44.
  215. Book: Gordon JD . Obstetrics, Gynecology & Infertility: Handbook for Clinicians. 2007. Scrub Hill Press, Inc.. 978-0-9645467-7-6. 228–.
  216. Contraceptives. Case for public enquiry. Economic and Political Weekly. 1994. 29. 15. Popline database document number 096527. 825–6.
  217. Sorojini NB . Why women's groups oppose injectable contraceptives . . 13 . 1 . January–March 2005 . dead . https://web.archive.org/web/20060506074850/http://www.issuesinmedicalethics.org/131di008.html . 6 May 2006 .
  218. Web site: Reference Manual for Injectable Contraceptive (MPA). 26 February 2020. nhm.gov.in.
  219. Web site: Boscoe M . Canadian Coalition on Depo-Provera letter to The Honorable Benoit Bouchard, National Minister of Health and Welfare . 6 December 1991 . Canadian Women's Health Network . 22 August 2006. https://web.archive.org/web/20070205105907/http://www.cwhn.ca/resources/birth_control/depoLetter.html. 5 February 2007.
  220. Web site: Class action suit filed over birth control drug . CTV.ca . 19 December 2005 . 22 August 2006 . dead . https://web.archive.org/web/20060813180129/http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20051219/depo_provera_051219/20051219?hub=TopStories . 13 August 2006 .
  221. "News: Israeli minister appointing team to probe Ethiopian birth control shot controversy . Haaretz . 20 June 2015 . live . https://web.archive.org/web/20150620062920/http://www.haaretz.com/news/israel/israeli-minister-appointing-team-to-probe-ethiopian-birth-control-shot-controversy-1.506266 . 20 June 2015 .
  222. Leary WE . U.S. approves injectable drug as birth control . The New York Times on the Web . A1, A14 . October 1992 . 11646958 . live . https://web.archive.org/web/20081208133159/http://query.nytimes.com/gst/fullpage.html?sec=health&res=9E0CE1DD123BF933A05753C1A964958260 . 8 December 2008 .
  223. Web site: Progestins (IARC Summary & Evaluation, Supplement7, 1987). 15 October 2016. live. https://web.archive.org/web/20171107030422/http://www.inchem.org/documents/iarc/suppl7/progestins.html. 7 November 2017.
  224. Goodman A . The Case Against Depo-Provera - Problems in the U.S . Multinational Monitor . February–March 1985 . 6 . 2 & 3 . live . https://web.archive.org/web/20061003000448/http://www.multinationalmonitor.org/hyper/issues/1985/02/problems-us.html . 3 October 2006 .
  225. Controversy over Depo-Provera . Washington Drug & Device Letter . 9 . 1 . 2 . January 1977 . 12335988 .
  226. Thomas DB, Ye Z, Ray RM . Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). WHO Collaborative Study of Neoplasia and Steroid Contraceptives . Contraception . 51 . 1 . 25–31 . January 1995 . 7750280 . 10.1016/0010-7824(94)00007-J .
  227. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives . Contraception . 45 . 4 . 299–312 . April 1992 . 1387601 . 10.1016/0010-7824(92)90052-U .
  228. Thomas DB, Ray RM . Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives . Contraception . 52 . 5 . 307–12 . November 1995 . 8585888 . 10.1016/0010-7824(95)00215-V .
  229. Shapiro S, Rosenberg L, Hoffman M, Kelly JP, Cooper DD, Carrara H, Denny LE, du Toit G, Allan BR, Stander IA, Williamson AL . Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) . Cancer Causes & Control . 14 . 5 . 485–95 . June 2003 . 12946044 . 10.1023/A:1024910808307 . 34683749 .
  230. Kaunitz AM . Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer . The Journal of Reproductive Medicine . 41 . 5 Suppl . 419–27 . May 1996 . 8725705 .
  231. Sterilization of minors leads to controversy . Family Planning/Population Reporter; A Review of State Laws and Policies . 2 . 4 . 77–8 . August 1973 . 12257656 .
  232. Egan TM, Siegert RJ, Fairley NA . Use of hormonal contraceptives in an institutional setting: reasons for use, consent and safety in women with psychiatric and intellectual disabilities . The New Zealand Medical Journal . 106 . 961 . 338–41 . August 1993 . 8341476 .
  233. Web site: Hawkins K, Elliott J . 5 May 1996 . Seeking Approval . 21 November 2015 . dead . https://web.archive.org/web/20151121180041/http://www.monitor.net/monitor/controlled/bc-depohearing.html . Albion Monitor . 20 November 2006 .
  234. Singh S . Adolescent knowledge and use of injectable contraceptives in developing countries . The Journal of Adolescent Health . 16 . 5 . 396–404 . May 1995 . 7662691 . 10.1016/S1054-139X(94)00060-R .
  235. Clinicians clash with consumer groups over possible Depo ban . Contraceptive Technology Update . 16 . 1 . 11–4 . January 1995 . 12319319 .
  236. Toppozada M . The clinical use of monthly injectable contraceptive preparations . Obstet Gynecol Surv . 32 . 6 . 335–47 . June 1977 . 865726 . 10.1097/00006254-197706000-00001 .
  237. Book: Goldzieher JW, Fotherby K . Pharmacology of the contraceptive steroids. 1994. Raven Press. 978-0-7817-0097-9. 154.
  238. Zañartu J, Rice-Wray E, Goldzieher JW . Fertility control with long-acting injectable steroids. A preliminary report . Obstet Gynecol . 28 . 4 . 513–5 . October 1966 . 5925038 .
  239. Book: Beckman H . The Year Book of Drug Therapy. 1967. Year Book Publishers.
  240. Book: Piotrowski Z, Greenberg RE . Prostate Cancer . Antiandrogen Monotherapy in the Treatment of Prostate Cancer. 2016. 515–521. Academic Press . 10.1016/B978-0-12-800077-9.00055-4. 978-0-12-800077-9.
  241. Book: Forster TH, Stoffel F, Gasser TC . Controversies in Uro-Oncology . Hormone therapy in advanced prostate cancer . 36 . 49–65 . 2002 . 11842755 . 10.1159/000061329 . 3-8055-7217-4 . Frontiers of Radiation Therapy and Oncology . 5 .
  242. Newling DW . The palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials . British Journal of Urology . 79 . Suppl 1 . 72–81 . March 1997 . 9088277 . 10.1111/j.1464-410X.1997.tb00805.x . free .
  243. Book: Denis LJ, Griffiths K, Kaisary AV, Murphy GP . Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment. 1 March 1999. CRC Press. 978-1-85317-422-3. 296–.
  244. Nieschlag E . Clinical trials in male hormonal contraception . Contraception . 82 . 5 . 457–70 . 2010 . 20933120 . 10.1016/j.contraception.2010.03.020 .
  245. Web site: Medroxyprogesterone - InKine - AdisInsight.
  246. Srinivasan R, Lichtenstein GR . Recent developments in the pharmacological treatment of Crohn's disease . Expert Opin Investig Drugs . 13 . 4 . 373–91 . April 2004 . 15102587 . 10.1517/13543784.13.4.373 . 22533823 .
  247. Saxena A, Scaini G, Bavaresco DV, Leite C, Valvassori SS, Carvalho AF, Quevedo J . Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature . Molecular Neuropsychiatry . 3 . 2 . 108–124 . November 2017 . 29230399 . 5701269 . 10.1159/000480349 .
  248. Simpson BS, Papich MG . Pharmacologic management in veterinary behavioral medicine . Vet. Clin. North Am. Small Anim. Pract. . 33 . 2 . 365–404, vii . March 2003 . 12701517 . 10.1016/S0195-5616(02)00130-4 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Medroxyprogesterone acetate".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.